Montag ist Celera Tag !!!!!!!! KZ 180 Dollar - 500 Beiträge pro Seite

[dj-cool]

Leute wir haben es geschafft, am Montag kommen die Big News!!!!
GGGGGGGGGGRRRRRRRRRRRRÖÖÖÖÖÖÖÖÖÖÖHHHHHHHHHHHLLLLLLLLLLLLLL

Mein Kursziel für Montag 180 Dollar!!!!!!!

Friday June 23, 7:00 pm Eastern Time
Company Press Release
ADVISORY/Celera Genomics and National Institutes of Health and Department of Energy News Briefing On Updates On the Human Genome
(BW HealthWire)--

WHO: J. Craig Venter, Ph.D., Celera Genomics, President and
Chief Scientific Officer

WHAT: Celera Genomics to hold news briefing to announce the
first assembly of the human genome. The NIH, DOE, and
international partners will announce a working draft of
the human genome.

WHEN: MONDAY, JUNE 26, 2000
12:30 PM EDT

WHERE: Join us at the Capitol Hilton
1001 16th Street, NW
Washington, DC 20036

Company Background

Celera`s mission is to become the definitive source of genomic and related medical and biological information. Users of Celera`s information, available on a subscription basis to academic and commercial institutions, will have access to tools for viewing, browsing and analyzing data in an integrated way that will assist scientists in accelerating their understanding of the human genetic code.

PE Corporation comprises two operating groups. The PE Biosystems Group (NYSE:PEB - news), with sales of $1.2 billion during fiscal 1999, develops and markets instrument-based systems, reagents, software and contract services to the life science industry and research community. The Celera Genomics Group (NYSE:CRA - news), headquartered in Rockville, MD, intends to become the definitive source of genomic and related medical information. PE Biosystems is headquartered in Foster City, CA, and comprises four divisions: Applied Biosystems, PE Informatics, PerSeptive Biosystems, and Tropix. Information about the Company, including reports and other information filed by the Company with the Securities and Exchange Commission, is available on the worldwide web at www.pecorporation.com or by phoning 800.762.6923.


Grüße an alle Celera Investoren und die die es noch werden !!!

DJ-Cool :-)))))

[lovergts]

Hallo dj-cool:

Ich kann Deine Begeisterung verstehen, doch sollten wir mit irgendwelchen Kurszielen am Boden bleiben. Entscheidend wird sein, was Venter noch OnTop bringen kann, denn die Entschlüsselung ist beim derzeitigen Kurs eingepreist. Für die Trader unter uns ist der Zeitpunkt 18:30Uhr gerade noch akzeptabel, um reagieren zu können. Wir werden einen EXTREM volatilen Kurs am Montag sehen und ich zweifle, daß wir die $180 sehen werden. Zuviele Zocker - und das sind wir letztendlich auch - sind in dieser Aktie drin.

[Garcia11]

Hey dj-cool

was soll denn diese üble Pusherei? Ein Thread sollte doch eigentlich ausreichen, um uns Deine Begeisterung über Celera mitzuteilen, oder nicht?

Das Bio-Board hat sich bis jetzt durch die Qualität der Beiträge ausgezeichnet und nicht durch "Irrational Exuberance".

Carpe Diem
Garcia

[Captain Cash]

@garcia11 ... wasn los, bis wohl bissl neidisch dassdes nich unter 100 rein bist ?
Was dj-cool macht is ja wohl alles andere als pusherei. Ausserdem könnte er den kurs maximal 1-2% pushen und das auch nur wenn er mehr machen würde. Also bleib realistisch und sprech nich von gepusche wenn mal einer nen posting 2x reinstellt.

Danke..
C $ C

[Real_Ceylon]

Genau Garcia, erscheint Dir dieses Kursziel so unrealistisch?

Ich weiß nicht... Ceylon

[el Brain]

Die vorbörslichen Kurse in den USA schwanken zwischen 115 und 135 USD. Der Handel ist zwar recht volatil, von Euphorie kann aber nicht die Rede sein.

[mjohn]

Hallo EL Brain !
Auf welcher Seite kann ich die vorbörslichen Kurse sehen ?
Vielen DANK
mjohn

[el Brain]

Hi Mjohn,

bei fast allen größeren Brokern. Bei www.etrade.com sind die Umsätze mit am höchsten und damit die Kurse einigermaßen aussagekräftig.

[Garcia11]

Also...

stimmt, ich bin "nicht unter 100 rein" !!! Wenn Ihr schon alle in Celera investiert seit, dann gönne ich Euch den potentiellen Kurserfolg vom ganzen Herzen, wirklich. Ob das Kursziel nun kurz/mittelfristig überzogen oder realistisch ist werden uns die kommenden Tage/Wochen zeigen.

Ich bin echt nicht der Typ, der gleich einen blöden Spruch macht, wenn jemand mal einen vorhandenen Thread nicht nutzt und stattdessen einen neuen aufmacht, quatsch. dj-cool hatte aber glaube ich 3 oder 4 mal gepostet, muss das sein?

Wie dem auch sei, also viel Erfolg mit Celera, mal schauen, vielleicht springe ich ja auch noch auf den fahrenden Zug.

Carpe Diem
Garcia

[dj-cool]

Hi Garcia11,

nochmal zu deinem Posting:

1. Du mußt es schon mir überlassen wie oft ich eine derartige
News poste, den diese News war eine die einen Meilenstein in der Genomforschung darstellt und natürlich auch eine die für uns Investoren oder Trader sehr wichtige war, da manche bereits 3 Wochen darauf warten!
2. Was das pushen angeht muß ich Dir eins sagen, was denkst Du eigentlich wieviel man den Kurs bewegen kann, wenn man hier etwas
postet? Wenns gut läuft 1 %!! Nur soviel dazu!!
3. Anstatt hier in Deinen Posting über Leute zu schimpfen die wichtige News posten (auch wenn es in vier Threads auf einmal war)
solltest Du vielleicht etwas konstruktives schreiben das auch für uns
informativ ist und nicht irgendwelches Gelabere wegen zuvielen Postings, denn solche Dummlaberer gibt es schon genug bei W(leider).

Nichts für ungut

DJ-Cool

[dj-cool]

Hier noch etwas zu Celera!!!

Sequencing the Genome of Something or Other

What does it mean on Monday when we (meaning our race) announce that we`ve sequenced the human genome? First, remember that words are only conventions that we use to label things. For example, we don`t really know what we are. We call ourselves "Human Beings," but what we really are is this: (Look in the mirror). And we don`t know what that is, despite the fact that we invented a name for it.

Similarly, laws of nature don`t exist in a way that society tends to believe. We seem to forget that we ascribed those laws to nature. "Laws" of nature were not discovered; they were invented. We named them like a matrix to fit over nature and define it for us because we`re a creature determined to define, classify and segment everything so that we can "understand it" (or so we can believe we understand it). The world itself doesn`t truly have any segmentation to it at all (we force that condition on it) -- so when you understand the world only through our dissection and labeling of its so-called parts, someone could argue that you don`t truly understand it at all.

The news that we`ve sequenced the human genome essentially means that we`ve separated and put into order the genes that have long existed in the body. Once again, we`ve taken nature and we`ve broken it into its smallest parts -- meaning we separate it into pieces that we can clumsily tag, segment and classify. Whether or not this proves to be a good thing in the long run, you and I may never know.

Manipulating genes, like manipulating atoms, will bring danger to the world as well as good. That`s to be expected, because you can never have good without its opposite, bad -- they arise mutually (and the meaning of one loses all meaning without its opposite to compare to). As horrible as disease is, it aids in keeping a population sustainable. If you learn to conquer disease, in the long run you may set the stage to conquer yourself.

Of course, we`re optimistic that the good will far overshadow the bad. To that end, today`s news from Human Genome Sciences (Nasdaq: HGSI) is an exciting demonstration of the power and speed of genomic discovery. In the spirit of investing in hope and promise, on Monday night the Rule Breaker will host a chat about biotechnology so we can discuss Celera (NYSE: CRA) , genome sequencing, biotech`s many leaders, and how to consider investing in them. We hope you`ll join us!

[CaptainChaos]

Die Beiträge von DJ - Cool haben in meinen Augen nur einen Sinn:
Börseneinsteiger sollen durch durch Beiträge in der Art von
Aufreissern a`la `Bild - Zeitung` animiert werden, den Kurs zu pushen, damit Leute wie DJ - Cool am nächsten Wochenende mit satten Kursgewinnen aussteigen können.

Ich habe heute morgen mit einem Studienkollegen in den USA telefoniert. De facto wird es in der nächsten Woche wirklich einen Biotech - Boom geben, wenn Darth Venter "Big News" verkünden sollte.Tatsächlich werden aber Firmen von einer 100-prozentigen Entschlüsselung der menschlichen Erbmasse profitieren, die im technischen Bereich arbeiten oder bereits Produkte in der Prüfphase III haben, bei denen "der letzte Schliff" fehlt. Aufgrund der gesetzlichen Vorgaben in den USA wird Venter viel Ehr und Ruhm einstreichen ( Nobel - Preis?), jedoch aufgrund von Patentgesetzen keinen Cash mit seinen Forschungsergebnissen einstreichen. Die Ergebnisse werden den gesamten Biotech - Sektor beflügeln. Um zu alten Höchstständen bei CRA zu gelangen, bedürfte es m.E. unbedingt einer wirtschaftlichen "Verwertung" der Forschungsergebnisse durch entsprechende Patentgesetze. Mein Spezi im Land der unbegrenzten Möglichkeiten teilte mit, dass viele Amerikaner aufgrund der Medienberichterstattung aufspringen werden und den Kurs in die Höhe treiben werden. Sobald aber in den Medien veröffentlicht wird, dass
Celera nicht den absoluten Cash aus seiner Forschungsarbeit erzielt, wird die Blase platzen. Und wann das sein wird, weiss leider keiner.
Ich bin davon überzeugt, dass CRA hochspekulativ ist. Ich vermeide im übrigen auch, Firmen, die nach meiner Auffassung die Gewinner dieser hervorragenden Forschungsarbeit sein werden, zu benennen, um mich nicht der Pusherei bezichtigen lassen.
Sorry DJ-Cool, aber Dein Versuch andere Leute zu hochspekulativen Geschäften zu bringen, dient ausschliesslich Deinem Cash. Vielleicht kannst Du ja Fakten bringen, die begründen, dass eine Celera - Aktie wirklich 180 $ wert ist. Vor der Clinton - Blair - Vereinbarung hätte ich Dir Recht gegeben. Zum jetzigen Zeitpunkt kann ich mich Deiner Auffassung nicht anschliessen.

Gruss

[stockstudi]

Also,soweit ich das mitverfolge,hat dj cool mit keinem Wort erwähnt,daß celera 180$ wert sei,sondern lediglich ,daß er erhwartet,daß dieses Kursziel erreicht wird. Gehen wir mal von der Meldung aus,die vor einigen Wochen bekannt gab,daß celera die Rohdaten der DNS ermittelt hat aus: Diese Nachricht sorgte für einen Kurssprung von ca 100% innerhalb von 3 Tagen.Nun soll bekannt gegeben werden,daß auch die anordnung der,,Puzzleteile" beendet ist und die Genkarte eines Menschen als Entwurf beendet ist.Also meine Auffassung ist ,daß sich diese News auf gar keinem Falle negativ auswirken wird,sondern im Gegenteil ich halte einen Kurssprung nach oben für das wahrscheinlichere Szenario. Werde mit stop/loss arbeiten und denke ,daß es zumindest für 2-3 Tage nach Norden geht. Außerdem halte ich laut meinen informationen Herrn Venter nicht für einen Wohltäter an der Menschheit. Er wird nicht in Zusammenarbeit mit der Regierung eine Veröffentlichung tätigen,aus der er keinen kommerziellen Nutzen ziehen wird. Wer macht schon gerne enorme Publicity für seinen Feind?
Außerdem ist die Frage nach Patenten zum jetzigen Zeitpunkt so geregelt,daß bei erfolgreicher Zuordnung der einzelnen Sequenzen sehr wohl ein kommerzieller Nutzen aus diesen gezogen werden kann.

Wir werden sehen!

[Garcia11]

Also dj-cool,

jetzt muss ich ja auch noch mal zu Deinen "Vorwürfen" mir gegenüber Stellung nehmen:

1. natürlich überlasse ich es Dir, wie wieviele Threads Du mit dem gleichen Inhalt veröffentlichst. Da hat ja keiner von uns einen Einfluss drauf. Jedoch sehe ich nicht ganz den Sinn, der dahinter stehen soll. Ich denke mal an Seriösität werden Deine Aussagen so nicht gewinnen, wenn Du sie nur wiederholst, oder?

2. Natürlich hat keiner von uns hier einen Einfluss darauf, wie sich die Nasdaq-Kurse entwickeln. Die Amis interessiert ja zum Glück auch nicht, welche Aktien Bernd F. aus Kulmbach empfiehlt. Wenn das so wäre, würde das Niveau des Boards ganz schnell den Bach runter gehen.


3. Ich habe hier noch niemals über irgendeinen User "geschimpft" !!! Und habe auch nicht vor, dieses in Zukunft zu tun. Ich möchte mich auch nicht von Dir provozieren lassen, wenn Du jetzt hier in Bezug auf meine Aussage von "Gelabere" oder "Dummlaberer" sprichst.
Wenn Du meinst, dass Du mit Deinem Posting ( "...GGGGGGGGGGRRRRRRRRRRRRÖÖÖÖÖÖÖÖÖÖÖHHHHHHHHHHHLLLLLLLLLLLLLL..." )einen "konstruktiven Beitrag" schreibst, dann möchte ICH Dir den Glauben nicht nehmen. Das mag jeder Leser selber beurteilen. Ich persönlich bin so langsam dabei mich in das komplexe Thema Biotechnologie einzuarbeiten und versuche so gut es geht meinen Beitrag hier zu leisten. Ich würde mich aber niemals auf eine Stufe mit IWA Japan oder Montana stellen, die WIRKLICH KONSTRUKTIVE BEITRÄGE schreiben.

D´arcore ??????

Gruß Garcia

[Shopping]

Hallo aus USA. Saemtliche Zeitungen hier hatten Samstag Celera auf der Titelseite. Ich denke das Montag Bewegung in den Kurs kommt

[dj-cool]

Also nochmal an alle Leute die mich zum Pusher machen!!!

Pushen in Deutschland ist leider nicht möglich da die Aktie im Amiland gehandelt wird und der Kurs sich in D auch nur daran anpasst!!
Pushen in dem ich hier poste: "Mein Kursziel 180 $" !!!!
Kommt Ihr Euch nicht ein bißchen lächerlich vor?? Erstens habe ich die Meldung für Leute wie Trader13, CaptianCash usw. gepostet die in allen Celera Threads bereits dabei waren und die diese Aktie langfristig und ebenfalls kurzfristig (wegen der hohen Volit) schätzen.

Sorry ! Was das "Gröhl" bedeutet, sorry hatte mich eben wegen der Nachricht gefreut!!

Garcia wenn Du meine Beiträge alle mal lesen würdest findest Du sicherlich nur konstruktive und informative Postings!!

Was andere User angeht Garcia, sie nehmen auch nur die News und die Meinungen von Fachzeitschriften und Analysten sowie Charttechnische
Informationen her um Ihre Beiträge zu gestalten!!

DJ-Cool

[mc.donaldo]

Celera sind bestimmt für 100 % in 2000 noch gut.

Meine Favoriten für 200-300 Prozent sind in 2000 nun metabox und SER-Syteme. Beide haben ein KGV v. 10 respektive 17 und enorm viel
Phantasie. Denn SERbrainware ist insbesondere auch im Biobereich eine wertvolle Hilfe.

Die Deutsche Telekom hat in eine Workflow-Unternehmenslizenz von CSE Systems GmbH - heute SERfloware GmbH,
Tocher von SER-Systeme investiert. Diese wird von der Deutschen Telekom nun in verschiedenen Projekten von Flensburg
bis München eingesetzt.
Unter insgesamt 12 Anbietern von Workflow-Lösungen setzte sich SERfloware gegen andere Konzepte durch.

Eine Frage der Zeit, bis sich der Kommunikationsriese auch für SERbrainware entscheidet? Brainware ist die lernfähige
Software-Engine, die
in allen Branchen und insbesondere im Internet eingesetzt werden kann. Es gibt nur einen Wettbewerber und dies ist
Autonomy. Und
Autonomy ist bekanntermaßen zur Zeit 10 mal so hoch bewertet und SER hat nach eigener Aussage das bessere Produkt und
will
Autonomy in 2000 deutlich überholt haben.

Die Kontakte sind jedenfalls geknüpft.

Also wenn die Deutsche Telekom SER-FLOware einsetzt, heißt dies es ist nur eine Frage der Zeit, daß somit auch
Deutschland größtes herstellerneutrales IT-Dienstleistungs-Unternehmen
debis Systemhaus, ca. (26.000 Mitarbeiter) welches ja nun mehrheitlich zu über 50,1 % zur Telekom gehört hier mittelfristig
ebenfalls SER-FLOware seinen Kunden
im Rahmen von Full-Services oder reinen Lizenzgeschäften anbieten bzw. bei sich im Konzern ebenfalls einsetzen wird.
Möglicherweise ist bei DaimlerChrysler, welches an debis-Systemhaus auch noch 49,9 % Anteile hält, weiterer Umsatz
möglich.
Durch die hervorragenden Kontakte zu allen Großkonzernen Europas v. debis Systemhaus ergeben sich hervorragende
Aussichten somit für uns! Kursziel laut Vorstand 250 bis 2002. Somit auf 500 % Kursteigerung bei dem derzeitigen KGV v.
17 ist SER-Systeme somit ein klarer Kauf. Natürlich sind metabox mit KGV v. 10 mit SER die beiden NM-Favoriten im Jahr
2000

[dj-cool]

Guten Morgen!!

So Celera ist mit 145 Euro in den Tag gestartet und wir werden sehen
wie sich der Kurs im Amiland entwickelt!!
Meiner Meinung nach wird sich die Bekanntgebung nicht negativ für Celera entwickeln da in Amerika die Leute einen regelrechten Run auf die Aktie starten werden!!
Sollte natürlich Clinton wieder etwas von wegen freie Veröffentlichung der Daten sagen so könnte das auch zu Kursstürzen führen!!
Man sollte aber nicht vergessen das Venter bisher immer ein As im Ärmel gehabt hat und er sicherlich nicht das letzte Jahr für die Allgemeinheit geforscht hat!!! Außerdem entspricht es nicht Venters Art sich geschlagen zu geben und die Daten einfach herzugeben.
Alles andere wird sich dann heute nach Pressekonferenz ergeben und wir werden sehen was Venter zu seinem besten gibt!!
Ich persönlich denke wir werden heute noch etwas überrascht und das im positiven Sinne!!
Deshalb mein Tip für heute 180 $!! Ich betone "mein Tip"

Für alle die sich genötigt fühlen zu sagen ich würde hier pushen:

1. Meine Aktien habe ich über ein Trader-Konto in den USA gekauft, deswegen ist es mir herzlich egal was der Kurs in Europa macht!
2. Alle die hier kaufen (ob Anfänger oder nicht) weil jemand ein persönliches Kursziel oder irgendeine News oder Analystenmeinung
postet und sich nicht dann ein eigenes Bild macht, (d.h. er prüft die Nachrichtenlage, schaut sich Fundamentaldaten an, liest Analystenmeinungen, geht den Quellenangaben in den Postings nach etc.) dem geschieht es recht wenn er eine Niete kauft oder er Verlust macht!! Das ist jetzt nicht böse gemeint denn jeder macht am Anfang Fehler (ich habe auch meine Fehler am Anfang gemacht), aber eine der Grundregelen bei Aktien ist nunmal das man eigene Research betreibt und dann sich selber eine Meinung bildet!!
Andre Kost. : "Kaufe nie eine Aktie von der Du nicht überzeugt bist"
"My nose is my castle"

So damit hat sich das Theme pushen für mich erledigt!!



Hier noch ein Artikel zu Celera.

Monday June 26, 3:14 am Eastern Time
Scientists close to completing book of life
LONDON, June 26 (Reuters) - Researchers are expected to announce a milestone in scientific history on Monday with news that they have mapped most of the human genetic code.

The race to complete the so-called book of life has been long awaited and closely fought.

The achievement is a scientific landmark akin to the discovery of the smallpox vaccine and penicillin or the landing of human beings on the moon.

It will change society, revolutionise medicine and alter the way diseases are detected and treated.

The announcement, expected at 1000 GMT, will also end months of speculation over which group of scientists would be the first to map the bulk of the raw DNA sequence that provides the basic instructions for the development of a human being.

U.S. biotechnology company Celera Genomics Inc (NYSE:CRA - news) and the publicly funded Human Genome Project were in a tight race, but the international collaborative effort seems to have edged past the private venture.

Barring any last-minute surprises, statements in Washington and London are expected to be the first official confirmation of what has been an open secret for months.

The Human Genome Project is supported mostly by the National Institutes of Health in the United States and Britain`s Wellcome Trust, the world`s largest medical research charity. It has been publishing its information on the Internet daily.

Celera Genomics Inc, based in Rockville, Maryland, has not revealed its data but has promised to make it available

[dj-cool]

So die Nasdaq hat geöffnet und Celera ist mit 132 Dollar in den Tag gestartet. Danach ist sie nach ein paar massiven Verkäufen (die auf die teilweis negative Presse bezüglich der Vermarktung der Daten zurückzuführen sind) auf 126,5 Dollar gefallen. Mittlerweile ist sie nach stetigen Käufen (norm. Volumen) gestiegen und steht im Moment bei 129 7/8 Dollar!
Ich möchte noch anmerken, daß bis zum jetzigen Zeitpunkt noch keine offizielen Meldungen darüber vorliegen was auf der Pressekonferenz mitgeteilt und besprochen wurde!!
Also nicht zu früh verkaufen und abwarten!
So binnen 5 Minuten haben die Käufe stark angezogen und der Kurs steht
aktuell bei 134 3/4 Dollar und seit 20 Minuten nur Käufe!
Denke das gibt Anlass zum hoffen!!

So what DJ-Cool

[stockstudi]

Bleib am Ball! Ich zähl auf Deine News!

[dj-cool]

Public, private teams cooperate on genome-Clinton
WASHINGTON, June 26 (Reuters) - The public and private groups who mapped the collection of human genes will cooperate in publishing that knowledge, ending months of competition and acrimony, U.S. President Bill Clinton said on Monday.

``The public and private research teams are committed to publishing their scientific data together later this year,`` Clinton told a ceremony at the White House called to mark the twin achievements.

Celera Genomics Inc. (NYSE:CRA - news), a Rockville, Maryland-based company funded with the specific purpose of being the first to map the human genome, said it had finished the sequence and assembled the genetic code.

The Human Genome Project, a collegial and publicly funded international effort that has been working toward the same goal for 10 years, said it had finished a rough draft of the genome.

The two sides had been negotiating on how best to make the information public and it was not clear that they would be able to reach an agreement. The Human Genome Project has been publishing the information as it progresses, while Celera wants to protect corporate rights to the information.

[dj-cool]

So die Meldung ist raus!! (Siehe vorhergehendes Posting)

Darin geht es aber nur um eine Zusammenarbeit beider Forschungsunternehmen!!

Ungeklärt bleibt die Frage der Vermarktung!!

Kurs ging auf 122 runter und ist aktuell wieder auf 130 7/8

Gerade eine neue News raus!!

Poste ich gleich

Grüße DJ Cool

[dj-cool]

War die gleiche Meldung die ich vorhin schon gepostet habe!!

Wahnsinnsvolatilität heute!! Denke das wird anhalten bis das mit der Vermarktung gekärt ist!!

Kurs aktuell: 126 1/8

DJ-Cool

[dj-cool]

Es bleibt weiter interessant!!

Venter hält laut dieser Meldung erst um 12.30 Uhr Eastern Time seine Pressekonferenz.
D.h. 18.30 Uhr bei ins!!

Aktueller Kurs: 123 Dollar

DJ-Cool

[dj-cool]

NEW YORK (CBS. MW) -- Celera Genomics and scientists from the government-funded Human Genome Project will unveil Monday a rough draft of the sequence of the human genome, which contains human genetic code.

The blueprint, which is the first assembly of the DNA sequence that makes up the code, will help shed light on how genes influence health and disease. See related story.

Dr. Francis Collins, director of the National Institutes of Health’s National Human Genome Research Institute, Dr. Ari Partrinos, associate director of Science for Biological and Environmental Research at the U.S. Department of Energy, and Dr. J. Craig Venter, President and Chief Scientific Officer of Celera Genomics (CRA: news, msgs) will hold a news conference in Washington at 12:30 Eastern time.

The announcement represents a milestone in scientific discovery. And while it will usher in a new era of achievement in medicine, it’ll also end one of intense rivalry between the public and private efforts in their race to decipher the genetic code.

Begun formally in 1990, the U.S. Human Genome Project was coordinated by the U.S. Department of Energy and the National Institutes of Health. The project originally was planned to last 15 years, but rapid technological advances accelerated the expected completion date.

Rockville, Md.-based Celera (CRA: news, msgs) “emerged as a very effective competitor in a very short period of time,” said Robert Olan, an analyst at Chase H&Q. The company was formed in May, 1998 by PE Corp. and J. Craig Venter, a genomic scientist and founder of the Institute for Genomic Research.

In April, Celera said it completed sequencing the genome from one human being, reaching a biotech landmark months ahead of expectations. See story.

A month later, the company said it began to deliver partial assemblies to its database subscribers and that it expected to announce the complete assembly of the human genome in June.

Celera has said it expects that a comparison of the genomes of a mouse, fruit fly, human and other model organisms to open many new avenues of research that could lead to a better understanding of gene function and disease. Last month, Celera said it`s already sequenced about one-third of the base pairs, or letters of genetic code, contained in the DNA of a mouse. Base pairs are believed to specify important information in an individual`s genetic makeup.

Research competition

As the research race progressed, the relationship between the two “sides” became combative as well competitive. Behind-the-scenes efforts to forge an alliance between public and private efforts derailed, as each side accused the other of bad faith.

Earlier this year, reports surfaced that Celera had had a very public disagreement with the National Human Genome Research Institute. The two research groups, which had been negotiating since December, had hoped to form a partnership that would merge the international Human Genome Project with Celera`s efforts.

The effort appeared to have faltered over divisive disagreements about commercial use of the gene database. At the time, Celera’s chief executive, Venter said his company supported the goal of completing the gene map rapidly but was concerned that research it funded will be available for other companies to repackage and sell. Celera has said it supports global access to the human genome data and making the data available to researchers for free. The company still plans to license its proprietary database to biotech and drug firms, academic institutes and other researchers for $5 million to $15 million a year, according to Hoover’s.

Olan said that the two sides have likely resolved their differences to shift focus back to scientific discovery.

Robertson Stephens analyst Michael King said that while a first draft is a “remarkable achievement” that will help to accelerate an understanding of how genes function,” translating it into something of value isn’t quite as straightforward.” King said investors must remember that medicines resulting from that understanding are still years away.

The U.K’s Wellcome Trust, a major contributor of funding as well as research to the Human Genome Project, is also expected to make an announcement on the rough draft on Monday, King said.

[Geldrausch]

Die Pressekonferenz ist erst um 18.30 unserer Zeit !!
Das war ein Interview auf CNN.

Lasst euch nicht rauskegeln!
Gruß

[dj-cool]

Die Meldungen kommen im Minutenryhtmus!!!
Poste erstmal alles und kommentiere dann!NEW YORK (CBS.MW) -- Biotechnology stocks rose Monday morning, as investors snapped up shares in advance of a landmark announcement from Celera Genomics and scientists from the government-funded Human Genome Project.

Scientists will unveil a rough draft of the sequence f the human genome, which contains human genetic code. The blueprint, which is the first assembly of the DNA sequence that makes up the code, will help shed light on how genes influence health and disease. See full story.

Dr. Francis Collins, director of the National Institutes of Health’s National Human Genome Research Institute, Dr. Ari Partrinos, associate director of Science for Biological and Environmental Research at the U.S. Department of Energy, and Dr. J. Craig Venter, President and Chief Scientific Officer of Celera Genomics (CRA: news, msgs) was scheduled to hold a news conference in Washington at midday.

The NIH, the DOE and their international partners will announce “working draft” of the human genome, and Celera will announce the first assembly of the human genome.

The Nasdaq Biotech index ($IXBT: news, msgs) rose 0.9 percent in recent trading while the Amex Biotech Index ($BTK: news, msgs) gained 1.3 percent.

Among biotechnology movers, Celera rose 6 to 133; CuraGen (CRGN: news, msgs) was up 1 3/8 to 41 1/4 and Genentech (DNA: news, msgs) rose 2 15/16 to 153.

On the downside, Human Genome Sciences (HGSI: news, msgs) fell 3 19/64 to 142 5/64 and Affymetrix (AFFX: news, msgs) slipped 5 11/16 to 170

[dj-cool]

Celera Genomics Completes the First Assembly of the Human Genome
Assembled Genome Has 3.12 Billion Base Pairs
ROCKVILLE, MD.--(BW HealthWire)--June 26, 2000--Celera Genomics (NYSE: CRA - news), a PE Corporation business, today announced that it has completed the first assembly of the human genome, which has revealed a total of 3.12 billion base pairs in the human genome. An assembled genome is one where the location and order of the letters of genetic code along the chromosomes are known. Celera now begins the analysis and annotation phase.

Celera uses two independent approaches to assemble the human genome. First, Celera`s Whole Genome Shotgun Assembly utilizes all of the Celera generated sequence data from the DNA of five individuals. Celera assembled the human genome using 26.4 million sequences of 550 base pairs long for a total of 14.5 billion base pairs sequenced, or 4.6X sequence coverage. At 4.6X more than 99 percent of the genome is covered. Celera`s whole genome shotgun sequencing technique involves sequencing from both ends of the double strands of DNA sequence. Celera`s use of these paired end sequences is a key tool for assembling the genome.

Celera`s paired end-sequencing strategy has now produced paired sequence reads that cover the human genome 35.6 times or 35.6X of paired sequence and clone coverage. This unprecedented genome coverage was achieved using a new system for isolating fragments of DNA for sequencing developed by Celera scientists Hamilton Smith and Robert Holt. This new system enables Celera to obtain particularly long segments for sequencing derived from stretches of DNA 50,000 letters long. These long segments provided almost 50 percent of the paired sequence coverage and aided greatly in producing long stretches of accurately ordered DNA. In addition, Celera included data from GenBank, the public database, produced primarily by the public genome effort. In order to eliminate any bias to the assembly associated with the incomplete map and assembly information from the GenBank data, Celera shredded the data into 13.6 million segments 550 base pairs long for a total of 7.48 billion base pairs. These data produced additional redundancy.

The calculation to perform the assembly involved 500 million trillion base to base comparisons requiring over 20,000 CPU (central processor unit) hours on Celera`s supercomputer. This believed to be the largest computational biology calculation to date.

The second assembly method used by Celera is its ``Regional Assembler.`` This is being used to cross validate the results from the whole genome shotgun assembly. Celera used the bacteria artificial chromosome (BAC) data from GenBank sorted into regions along the chromosomes. Celera data was placed to the identified regions followed by the assembly into proper order utilizing Celera`s shotgun assembler. The results of this assembly process are sequence segments known as ``scaffolds`` reconstituting the 24 human chromosomes. Most of the genome is covered by sequence scaffolds of one million base pairs or larger.

``To say that the completion of this first assembly of the human genome is an exciting milestone for Celera and its scientific staff, is an understatement. We have assembled 3.12 billion letters of genetic code and know for the first time in history the order and orientation of this information,`` said J. Craig Venter, Ph.D., Celera`s president and chief scientific officer. ``I also want to congratulate our colleagues associated with the public genome effort on their working draft sequence. Celera will now move to the next phase of annotation whereby these located genes are studied to better understand their function. Celera subscribers will now be able to compare genetic data from the fruit fly, human and mouse in order to make discoveries that could lead to improved treatments and possible cures for disease.``

``Our announcement today of the first assembly of the human genome and that of a working draft by the publicly funded human genome project are significant achievements in science,`` said Tony White, PE Corporation`s chairman, president and chief executive officer. ``We are also proud of the contributions that PE Biosystems, Celera`s sister business, has made to these accomplishments by providing the sequencing instruments, which were so essential for both Celera`s sequence and the public working draft.``

Whole Genome Sequencing

Celera began to sequence the human genome on September 8, 1999, using the whole genome shotgun technique that its scientists pioneered in sequencing the first complete genome in 1995 at The Institute for Genomic Research (TIGR). This technique involves randomly shearing the human chromosomes into millions of pieces of 2,000 and 10,000 base pairs in length. The chromosome fragments are inserted into a plasmid vector and propagated in E. coli to produce millions of copies of each fragment. Celera scientists then sequence both ends of each fragment. The millions of sequences representing billions of letters of genetic code are then assembled into the proper order using proprietary genome assembly algorithms and the powerful Celera supercomputing facility. This results in the reconstruction of the linear sequence of the 23 pairs of human chromosomes.

The human genome sequencing effort funded by governments and the Wellcome Trust is based on sequencing large segments of human DNA in bacterial artificial chromosomes (BAC) using a variation of the shotgun sequencing method. With this approach, approximately 30,000 BAC clones have to be sequenced and their order mapped to reassemble the 23 human chromosomes. There are on average 150,000 letters of human DNA in a BAC. Its ``draft`` sequence represents most of these base pairs; however the fragments of DNA sequence are largely unordered. By combining the Celera whole genome data with the individual clone ``draft`` BAC data, Celera orders the sequence within each BAC segment and then places them in the proper order to construct the genome`s sequence. Celera has simultaneously and independently assembled the genome with its whole genome assembly algorithms. The combination of these two complementary genome sequencing and assembly approaches has greatly reduced the time necessary for Celera to finish the sequence and assembly of the human genome.

Celera`s Donor Pool

Celera follows a strict Institutional Review Board (IRB) protocol, which allows for a pool of up to 30 individuals to be recruited for the human genome sequencing effort. Recruitment was done via self-referral, newspaper ads, and outreach activities to ensure ethnic diversity. Five individuals have been chosen from Celera`s donor pool. These donors are men and women from a variety of self-disclosed ethnic backgrounds.

Celera`s Technology

Celera has rapidly sequenced and assembled the fruit fly genome and the human genome, and has nearly completed half the sequencing of the mouse genome. The speed with which Celera is capable of doing this is directly attributable to the state-of-the art technology employed in various stages of the sequencing process. Celera has 300 ABI PRISM® 3700 automated sequencers in its high-throughput DNA sequencing factory. These machines, made by PE Biosystems and developed by the PE Biosystems` team led by its president Michael Hunkapiller, Ph.D., have enabled researchers worldwide to use this process on an industrial scale for the first time. Prior to its production in 1999, researchers spent months, if not years, sequencing portions of the genome.

Another key to Celera`s success in genomic sequencing has been the development of high performance supercomputing technology. Celera`s computing partner is Compaq Computer Corporation. In completing the sequencing and assembly of the 3.12 billion letters of genetic code, Celera relied exclusively on networked Compaq AlphServer computers running Tru64 UNIX and TruCluster software to manage the more than 80 terabytes of data and to perform what are believed to be some of the most complex computations in the history of supercomputing. Celera`s final assembly computations were run on Compaq`s new AlphaServer GS160 because the algorithms and data required 64 gigabytes of shared memory to run successfully. Celera also has an alliance with Oracle for complete database development and infrastructure for all planned Celera Genomics databases, including Drosophila (fruit fly), human, mouse, rice and Arabidopsis (mustard weed).

Celera Milestones

While assembly of the human genome represents the achievement of one of Celera`s most significant scientific goals, Celera management has consistently explained that it represents more of a starting line than a finish line in the genomics revolution. Several areas continue to fuel activity at Celera, and these efforts feed Celera`s business model. These areas include the following:


-- Human Genome

On January 10, 2000, Celera announced it had compiled data
covering 90% of the human genome. On April 6, 2000, Celera
announced it had completed the sequencing phase of the genome from
one human being. With today`s announcement, Celera has completed
the assembly phase of the genome. Celera now begins the phase
known as annotation whereby the located genes are further analyzed
to start the process of understanding their particular function.
Celera is on target to submit a paper for publication on the
consensus genome later this year. Upon publication, the data will
be freely available to academic researchers worldwide via Celera`s
web site. Celera`s academic, pharmaceutical, and biotechnology
subscribers have immediate access to the database and
sophisticated bioinformatics tools for analysis of the genome.
Other database companies will not be able to redistribute Celera`s
data.

-- Mouse Genome

Celera announced on June 1, 2000 that it has sequenced
approximately 1.15 billion base pairs of mouse DNA. Celera began
to sequence the mouse on April 6, 2000. This project is of
critical importance to biomedical researchers using the mouse as a
model organism for studies of human biology and medicine. Having
access to the mouse genome should allow researchers to make
important discoveries in the regulation of human genes based on
common structure and mechanisms shared with mouse genes. Celera is
now on target to complete the sequencing of the mouse by the end
of 2000. Celera anticipates sequencing other species to aid with
comparative genomics.

With continued development and expansion of Celera`s unique databases, sales of subscriptions to commercial and academic users will be a priority. Celera also will continue to pursue avenues, both directly and by partnering with others, to generate value through discovery efforts based on extending sequencing data to biological and medical breakthroughs.

PE Corporation comprises two operating groups. The PE Biosystems Group (NYSE: PEB - news), with sales of $1.2 billion during fiscal 1999, develops and markets instrument-based systems, reagents, software and contract services to the life science industry and research community. The Celera Genomics Group (NYSE: CRA - news), headquartered in Rockville, MD, intends to become the definitive source of genomic and related medical information. PE Biosystems is headquartered in Foster City, CA, and comprises four divisions: Applied Biosystems, PE Informatics, PerSeptive Biosystems, and Tropix. Information about the company, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the worldwide web at www.pecorporation.com or by phoning 800.762.6923.

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as ``believe,`` ``expect,`` ``anticipate,`` ``should,`` ``intend,`` ``planned,`` ``estimated,`` and ``potential,`` among others. These forward-looking statements are based on PE Corporation`s current expectations. The Private Securities Litigation Reform Act of 1995 provides a ``safe harbor`` for such forward-looking statements. In order to comply with the terms of the safe harbor, PE Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Celera Genomics` businesses include but are not limited to (1) operating losses to date; (2) a unique and developing business plan; (3) dependence on the timely completion of the sequencing and assembly of the human genome; (4) uncertainty of revenue growth; (5) unproven use of genomics information to develop products; (6) intense competition in the evolving genomics industry; (7) dependence on customers in and subject to the risks of the pharmaceutical and biotechnology industries; (8) heavy reliance on strategic relationship with the PE Biosystems group; (9) potential product liability claims; (10) liabilities related to use of hazardous materials; (11) lengthy sales cycle; (12) dependence on the unique expertise of its scientific and management staff; (13) uncertainty of patent, copyright and intellectual property protection; (14) dependence on computer hardware, software, and internet applications; (15) access to biological materials; (16) legal, ethical and social issues affecting demand for products; (17) disruptions caused by rapid growth of the business; (18) government regulation of its products and services; (19) risks of future acquisitions; and (20) other factors that might be described from time to time in PE Corporation`s filings with the Securities and Exchange Commission.

Celera, Celera Genomics, and PE Biosystems are trademarks of PE Corporation.


--------------------------------------------------------------------------------

[dj-cool]

Kann mich meinem Vorredner nur anschließen!!
Alles was bis jetzt bekanntgegeben wurde beruht nur auf Aussagen von Mr. Bill Clinton, interessant ist auch das Clinton sagt das Celera das Genom komplett entschlüsselt und geordnet hat und HGB nur den größtenteil davon fertig hat!

Meldung von Celera:

Celera Genomics Completes the First Assembly of the Human Genome
Assembled Genome Has 3.12 Billion Base Pairs
ROCKVILLE, MD.--(BW HealthWire)--June 26, 2000--Celera Genomics (NYSE: CRA - news), a PE Corporation business, today announced that it has completed the first assembly of the human genome, which has revealed a total of 3.12 billion base pairs in the human genome. An assembled genome is one where the location and order of the letters of genetic code along the chromosomes are known. Celera now begins the analysis and annotation phase.

Celera uses two independent approaches to assemble the human genome. First, Celera`s Whole Genome Shotgun Assembly utilizes all of the Celera generated sequence data from the DNA of five individuals. Celera assembled the human genome using 26.4 million sequences of 550 base pairs long for a total of 14.5 billion base pairs sequenced, or 4.6X sequence coverage. At 4.6X more than 99 percent of the genome is covered. Celera`s whole genome shotgun sequencing technique involves sequencing from both ends of the double strands of DNA sequence. Celera`s use of these paired end sequences is a key tool for assembling the genome.

Celera`s paired end-sequencing strategy has now produced paired sequence reads that cover the human genome 35.6 times or 35.6X of paired sequence and clone coverage. This unprecedented genome coverage was achieved using a new system for isolating fragments of DNA for sequencing developed by Celera scientists Hamilton Smith and Robert Holt. This new system enables Celera to obtain particularly long segments for sequencing derived from stretches of DNA 50,000 letters long. These long segments provided almost 50 percent of the paired sequence coverage and aided greatly in producing long stretches of accurately ordered DNA. In addition, Celera included data from GenBank, the public database, produced primarily by the public genome effort. In order to eliminate any bias to the assembly associated with the incomplete map and assembly information from the GenBank data, Celera shredded the data into 13.6 million segments 550 base pairs long for a total of 7.48 billion base pairs. These data produced additional redundancy.

The calculation to perform the assembly involved 500 million trillion base to base comparisons requiring over 20,000 CPU (central processor unit) hours on Celera`s supercomputer. This believed to be the largest computational biology calculation to date.

The second assembly method used by Celera is its ``Regional Assembler.`` This is being used to cross validate the results from the whole genome shotgun assembly. Celera used the bacteria artificial chromosome (BAC) data from GenBank sorted into regions along the chromosomes. Celera data was placed to the identified regions followed by the assembly into proper order utilizing Celera`s shotgun assembler. The results of this assembly process are sequence segments known as ``scaffolds`` reconstituting the 24 human chromosomes. Most of the genome is covered by sequence scaffolds of one million base pairs or larger.

``To say that the completion of this first assembly of the human genome is an exciting milestone for Celera and its scientific staff, is an understatement. We have assembled 3.12 billion letters of genetic code and know for the first time in history the order and orientation of this information,`` said J. Craig Venter, Ph.D., Celera`s president and chief scientific officer. ``I also want to congratulate our colleagues associated with the public genome effort on their working draft sequence. Celera will now move to the next phase of annotation whereby these located genes are studied to better understand their function. Celera subscribers will now be able to compare genetic data from the fruit fly, human and mouse in order to make discoveries that could lead to improved treatments and possible cures for disease.``

``Our announcement today of the first assembly of the human genome and that of a working draft by the publicly funded human genome project are significant achievements in science,`` said Tony White, PE Corporation`s chairman, president and chief executive officer. ``We are also proud of the contributions that PE Biosystems, Celera`s sister business, has made to these accomplishments by providing the sequencing instruments, which were so essential for both Celera`s sequence and the public working draft.``

Whole Genome Sequencing

Celera began to sequence the human genome on September 8, 1999, using the whole genome shotgun technique that its scientists pioneered in sequencing the first complete genome in 1995 at The Institute for Genomic Research (TIGR). This technique involves randomly shearing the human chromosomes into millions of pieces of 2,000 and 10,000 base pairs in length. The chromosome fragments are inserted into a plasmid vector and propagated in E. coli to produce millions of copies of each fragment. Celera scientists then sequence both ends of each fragment. The millions of sequences representing billions of letters of genetic code are then assembled into the proper order using proprietary genome assembly algorithms and the powerful Celera supercomputing facility. This results in the reconstruction of the linear sequence of the 23 pairs of human chromosomes.

The human genome sequencing effort funded by governments and the Wellcome Trust is based on sequencing large segments of human DNA in bacterial artificial chromosomes (BAC) using a variation of the shotgun sequencing method. With this approach, approximately 30,000 BAC clones have to be sequenced and their order mapped to reassemble the 23 human chromosomes. There are on average 150,000 letters of human DNA in a BAC. Its ``draft`` sequence represents most of these base pairs; however the fragments of DNA sequence are largely unordered. By combining the Celera whole genome data with the individual clone ``draft`` BAC data, Celera orders the sequence within each BAC segment and then places them in the proper order to construct the genome`s sequence. Celera has simultaneously and independently assembled the genome with its whole genome assembly algorithms. The combination of these two complementary genome sequencing and assembly approaches has greatly reduced the time necessary for Celera to finish the sequence and assembly of the human genome.

Celera`s Donor Pool

Celera follows a strict Institutional Review Board (IRB) protocol, which allows for a pool of up to 30 individuals to be recruited for the human genome sequencing effort. Recruitment was done via self-referral, newspaper ads, and outreach activities to ensure ethnic diversity. Five individuals have been chosen from Celera`s donor pool. These donors are men and women from a variety of self-disclosed ethnic backgrounds.

Celera`s Technology

Celera has rapidly sequenced and assembled the fruit fly genome and the human genome, and has nearly completed half the sequencing of the mouse genome. The speed with which Celera is capable of doing this is directly attributable to the state-of-the art technology employed in various stages of the sequencing process. Celera has 300 ABI PRISM® 3700 automated sequencers in its high-throughput DNA sequencing factory. These machines, made by PE Biosystems and developed by the PE Biosystems` team led by its president Michael Hunkapiller, Ph.D., have enabled researchers worldwide to use this process on an industrial scale for the first time. Prior to its production in 1999, researchers spent months, if not years, sequencing portions of the genome.

Another key to Celera`s success in genomic sequencing has been the development of high performance supercomputing technology. Celera`s computing partner is Compaq Computer Corporation. In completing the sequencing and assembly of the 3.12 billion letters of genetic code, Celera relied exclusively on networked Compaq AlphServer computers running Tru64 UNIX and TruCluster software to manage the more than 80 terabytes of data and to perform what are believed to be some of the most complex computations in the history of supercomputing. Celera`s final assembly computations were run on Compaq`s new AlphaServer GS160 because the algorithms and data required 64 gigabytes of shared memory to run successfully. Celera also has an alliance with Oracle for complete database development and infrastructure for all planned Celera Genomics databases, including Drosophila (fruit fly), human, mouse, rice and Arabidopsis (mustard weed).

Celera Milestones

While assembly of the human genome represents the achievement of one of Celera`s most significant scientific goals, Celera management has consistently explained that it represents more of a starting line than a finish line in the genomics revolution. Several areas continue to fuel activity at Celera, and these efforts feed Celera`s business model. These areas include the following:


-- Human Genome

On January 10, 2000, Celera announced it had compiled data
covering 90% of the human genome. On April 6, 2000, Celera
announced it had completed the sequencing phase of the genome from
one human being. With today`s announcement, Celera has completed
the assembly phase of the genome. Celera now begins the phase
known as annotation whereby the located genes are further analyzed
to start the process of understanding their particular function.
Celera is on target to submit a paper for publication on the
consensus genome later this year. Upon publication, the data will
be freely available to academic researchers worldwide via Celera`s
web site. Celera`s academic, pharmaceutical, and biotechnology
subscribers have immediate access to the database and
sophisticated bioinformatics tools for analysis of the genome.
Other database companies will not be able to redistribute Celera`s
data.

-- Mouse Genome

Celera announced on June 1, 2000 that it has sequenced
approximately 1.15 billion base pairs of mouse DNA. Celera began
to sequence the mouse on April 6, 2000. This project is of
critical importance to biomedical researchers using the mouse as a
model organism for studies of human biology and medicine. Having
access to the mouse genome should allow researchers to make
important discoveries in the regulation of human genes based on
common structure and mechanisms shared with mouse genes. Celera is
now on target to complete the sequencing of the mouse by the end
of 2000. Celera anticipates sequencing other species to aid with
comparative genomics.

With continued development and expansion of Celera`s unique databases, sales of subscriptions to commercial and academic users will be a priority. Celera also will continue to pursue avenues, both directly and by partnering with others, to generate value through discovery efforts based on extending sequencing data to biological and medical breakthroughs.

PE Corporation comprises two operating groups. The PE Biosystems Group (NYSE: PEB - news), with sales of $1.2 billion during fiscal 1999, develops and markets instrument-based systems, reagents, software and contract services to the life science industry and research community. The Celera Genomics Group (NYSE: CRA - news), headquartered in Rockville, MD, intends to become the definitive source of genomic and related medical information. PE Biosystems is headquartered in Foster City, CA, and comprises four divisions: Applied Biosystems, PE Informatics, PerSeptive Biosystems, and Tropix. Information about the company, including reports and other information filed by the company with the Securities and Exchange Commission, is available on the worldwide web at www.pecorporation.com or by phoning 800.762.6923.

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as ``believe,`` ``expect,`` ``anticipate,`` ``should,`` ``intend,`` ``planned,`` ``estimated,`` and ``potential,`` among others. These forward-looking statements are based on PE Corporation`s current expectations. The Private Securities Litigation Reform Act of 1995 provides a ``safe harbor`` for such forward-looking statements. In order to comply with the terms of the safe harbor, PE Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Celera Genomics` businesses include but are not limited to (1) operating losses to date; (2) a unique and developing business plan; (3) dependence on the timely completion of the sequencing and assembly of the human genome; (4) uncertainty of revenue growth; (5) unproven use of genomics information to develop products; (6) intense competition in the evolving genomics industry; (7) dependence on customers in and subject to the risks of the pharmaceutical and biotechnology industries; (8) heavy reliance on strategic relationship with the PE Biosystems group; (9) potential product liability claims; (10) liabilities related to use of hazardous materials; (11) lengthy sales cycle; (12) dependence on the unique expertise of its scientific and management staff; (13) uncertainty of patent, copyright and intellectual property protection; (14) dependence on computer hardware, software, and internet applications; (15) access to biological materials; (16) legal, ethical and social issues affecting demand for products; (17) disruptions caused by rapid growth of the business; (18) government regulation of its products and services; (19) risks of future acquisitions; and (20) other factors that might be described from time to time in PE Corporation`s filings with the Securities and Exchange Commission.

Celera, Celera Genomics, and PE Biosystems are trademarks of PE Corporation.


--------------------------------------------------------------------------------

Nicht vorzeitig rausspringen!!

DJ-Cool

Kurs aktuell bei 119 Dollar

[bioaktiv]

Hallo DJ-Cool,
Es ist gar nicht so einfach cool zu bleiben. Wenn man hier alle Postings durchwühlt, stellt man fest, daß mehr als 90% der auf dem Prinzip `Hoffnung` basierenden Aussagen ein Flop waren. Ich sitze ja auch im `Celera-Boot` und würde gerne Konkretes zu deren vermarktbaren Produkten finden. Weiß wirklich niemand mit was Celera sein Geld verdienen will ? Fakten, keine Spekulationen wären sicher interessant für viele Celer(i)aner.

[matthze]

Hallo zusammen,

habe mich soeben von Celera verabschiedet für 125 Euro um 17.23h. Die Sache wird wohl jetzt doch zu heiß. Die News sind leider wenig überzeugend. Euch jedenfalls wünsche ich noch viel Glück!!
Russisches Roulette ist eben doch nicht mein Ding! ;-)

mfg Matthze

[lovergts]

....ich bleibe drin....

[take]

ich bleibe auch!

[dj-cool]

Da gebe ich Euch beiden vollkommen recht!!
Daran liegt es im Moment auch und deshalb geht der Kurs gen Süden
aktuell bei 112,5 Dollar! Venter hat seine Pressekonferenz noch nicht gehalten und bei den derzeitigen Meldungen (wie Ihr schon sagt) ist nichts postives für Celera dabei !!
Nach der derzeitigen Nachrichtenlage arbeitet Celera mit dem öffentlichen Projekt zusammen, woraus man schließen kann das Celera keinen Pfennig an Ihren Forschung verdienen wird da das HGP die Daten kostenlos im Internet anbietet bzw. zugänglich macht!! Das ist die Lage im Moment!!
Venter hat ebenfalls noch kein Geschäftsprojekt direkt vorgestellt! Andererseits läßt das Geschäft mit der Vanderbuilt University darauf schließen in welche Richtung die Vermarktung bzw. das Geschäft gemacht werden soll!!

Die Daten die Celera erforscht werden anderen Biotech Firmen Universitäten Forschungseinrichtungen etc. gegen Entgeld zur Verfügung gestellt, was durchaus ein Markt mit einem nicht zu geringem Kapital wäre, aber das endet schon wieder in Spekulationen!

Hoffe ich konnte weiterhelfen!!

Grüße DJ-Cool

aktueller Kurs: 110 Dollar

PS: Wenn ich ganz ehrlich bin dann werde ich langsam auch ein bißchen unsicher, aber ich bleibe drinnen!!

[Green_Ninja]

bleibe drin mit stop-loss
auf 95 !!!!!

usa im moment : 110$

cu

[lovergts]

So wie ich Venter einschätze, hat der sich diesen gemeinsamen Auftritt mit Collins und Clinton EINDEUTIG versilbern lassen. Der Mann ist doch nicht blöd. Daß der Kurs jetzt so in den Keller geht hat mehrere Gründe:

1. Sell on good news
2. massives shorten
3. Die "offizielle" Bekanntgabe (CNN) mit Clinton und Collins hatte eher den Charakter einer billigen Dreigroschen-Story.

P.S. Den Kursverfall habe ich genutzt um noch einige Celeras nachzulegen.

Viel Glück euch allen (und mir natürlich....)

[Captain Cash]

Was meint ihr is nen sinnvoller stopkurs (in E) ??
Will nich unnötig rauskugeln..
Hab auch bei 118 E noch ne portion aufgepackt und hoff nu auf ähnliche Käufe in den US
Sers...
C $ C

[CashCowCowboy]

Es gehört ja nun nicht wirklich viel Phantasie dazu mal zu überlegen, wo Celera in ein paar Monaten/Jahren stehen wird.
Es sei denn man hat auch nicht geglaubt, daß es nach der Dampfmaschine nich weitergeht.
Ist das ein amish board oder was?
CCC

[MSolver]

erst nachkaufen wenn sich der Kurs gedreht hat !
nicht zu früh nachkaufen !!!
cu

[Captain Cash]

Kurs hat bei 116 gedreht... bin grad noch mit 118 rein gekommen
Kann natürlich sein dass er nochmal dreht.. aber who cares.
Hab grad nen Bericht gelesen wie viele führende Genspezialisten auf der Gehaltsliste von Celera stehn und was diese an Ausrüstung haben. Ich muss sagen ich war echt beeindruckt und sehe nu echt Zukunft für den wert.
Hab ihn soeben von Kurz auf Mittelfristiges Investment hochgestuft..
Sers..

C $ C

[Shopping]

Monday June 26, 12:39 pm Eastern Time
Morningstar.com
Unlocking the Genome
By Emily Hall



A major step forward for biology and medicine--the first complete working draft of the human genetic code--was announced early Monday by officials from the government-sponsored Human Genome Project.


From a financial standpoint, however, such an achievement will not translate into immediate profits for genomics companies. Many firms seeking to profit from the mapping of the human genome, including PE Corp-Celera Genomics (NYSE: CRA - news), Incyte Pharmaceuticals (Nasdaq: INCY - news), and Human Genome Sciences (Nasdaq: HGSI - news), are still several years away from profitability.


One of the most interesting developments at the press conference at which the long-expected announcement was made was the public reconciliation between Francis Collins, head of the Human Genome Project, and Celera president J. Craig Venter. The federal program and Celera have been in a much-publicized race to complete the mapping of the human genome and had exchanged sometimes-heated rhetoric. But Collins and Venter congratulated each other Monday on their respective achievements.


Venter also indicated that Celera would participate in another press conference at 11:30 a.m. Central time Monday to announce the company`s completion of the first assembly of the human genome.


Despite the announcement, Celera`s stock was trading down more than 13% in intraday trading--an indication of the highly volatile and speculative nature of the genomics companies.


Emily Hall can be reached at [e-mail].

Visit www.morningstar.com daily for in-depth analysis of stocks, funds, and sectors in the news.

[Shopping]

Scientists unveil genetic blueprint

By Stephanie O`Brien, CBS.MarketWatch.com
Last Update: 1:18 PM ET Jun 26, 2000 NewsWatch
Latest headlines

NEW YORK (CBS. MW) -- Celera Genomics and scientists from the government-funded Human Genome Project unveiled a rough draft of the genetic code for human life, in what’s being hailed as one of mankind’s greatest scientific accomplishments.

The blueprint, which is the first assembly of the DNA sequence that makes up the code, will help shed light on how genes influence health and disease. The announcement represents a milestone in scientific discovery. And while it will usher in a new era of achievement in medicine, it’ll also end one of intense rivalry between the public and private efforts in their race to decipher the genetic code.

Begun formally in 1990, the U.S. Human Genome Project was coordinated by the U.S. Department of Energy and the National Institutes of Health. The project has partners in the U.K., France, Germany, Japan and China. It was planned originally to last 15 years, but rapid technological advances accelerated the expected completion date.

“This is a happy day for all of us,” Dr. Francis Collins, director of the National Institutes of Health’s National Human Genome Research Institute said at a news conference in Washington on Wednesday.

Collins said that while the announcement was much to celebrate, much more work lies ahead.

“We need to finish this job,” Collins said.

He said that while greater knowledge of how genes function will surely be the “source of blockbuster therapies of the future,” scientists will be studying the blueprint for decades to come.

Collins was joined by Dr. Ari Partrinos, associate director of Science for Biological and Environmental Research at the U.S. Department of Energy, and Dr. J. Craig Venter, President and Chief Scientific Officer of Celera Genomics (CRA: news, msgs)

Venter called the draft a “triumph for both public and private funding,” without which, completion would still be a long way off. He said the milestone will be a major driver science and medicine going forward.

Prior to the news conference, Celera said it completed the first assembly of the human genome, which has revealed a total of 3.12 billion base pairs. A genome is a complete set of genetic material contained in an organism`s chromosomes. Its size is generally given as its total number of base pairs.

Celera began sequencing the genome from one human being in April. An assembled genome is one in which the location and order of the letters of genetic code along the chromosomes are known. Celera said it now plans to study the genes to learn more about how they function.

On Monday, President Clinton pledged to “continue and accelerate the United States commitment” to help translate the blueprint into new treatments.

While praising the scientific achievement, Clinton also sought to assuage concerns about the potential misuse of powerful - and personal - information.

“This genetic information must never be used to stigmatize or discriminate against any individual or group,” Clinton said in remarks prior to a news conference on the genome. “Our scientific advances must always incorporate our most cherished values, and the privacy of this new information must be protected,” the President said.

Collins also called for vigilance and responsibility in dealing with the ethical, legal and social implications of

The President also addressed an area of concern in recent months: the accessibility of the data. He reiterated that the Human Genome Project’s sequencing data will be available for free to both public and privately funded researchers worldwide.

Celera, which makes its sequencing data available by subscription, will also make its version of the consensus human genome sequence available to non-subscribers upon publication.

The public and private efforts have not always presented a united front.

“Celera emerged as a very effective competitor in a very short period of time,” said Robert Olan, an analyst at Chase H&Q. The company was formed in May, 1998 by PE Corp. and J. Craig Venter, a genomic scientist and founder of the Institute for Genomic Research.

In April, Celera said it completed sequencing the genome from one human being, reaching a biotech landmark months ahead of expectations. See story.

A month later, the company said it began to deliver partial assemblies to its database subscribers and that it expected to announce the complete assembly of the human genome in June.

Celera has said it expects that a comparison of the genomes of a mouse, fruit fly, human and other model organisms to open many new avenues of research that could lead to a better understanding of gene function and disease. Last month, Celera said it`s already sequenced about one-third of the base pairs, or letters of genetic code, contained in the DNA of a mouse. Base pairs are believed to specify important information in an individual`s genetic makeup.

Research competition

As the research race progressed, the relationship between the two “sides” became combative as well competitive. Behind-the-scenes efforts to forge an alliance between public and private efforts derailed, as each side accused the other of bad faith.

Earlier this year, reports surfaced that Celera had had a very public disagreement with the National Human Genome Research Institute. The two research groups, which had been negotiating since December, had hoped to form a partnership that would merge the international Human Genome Project with Celera`s efforts.

The effort appeared to have faltered over divisive disagreements about commercial use of the gene database. At the time, Celera’s chief executive, Venter said his company supported the goal of completing the gene map rapidly but was concerned that research it funded will be available for other companies to repackage and sell. Celera has said it supports global access to the human genome data and making the data available to researchers for free. The company still plans to license its proprietary database to biotech and drug firms, academic institutes and other researchers for $5 million to $15 million a year, according to Hoover’s.

Olan said that the two sides have likely resolved their differences to shift focus back to scientific discovery.

Robertson Stephens analyst Michael King said that while a first draft is a “remarkable achievement” that will help to accelerate an understanding of how genes function,” translating it into something of value isn’t quite as straightforward.” King said investors must remember that medicines resulting from that understanding are still years away.

[bioaktiv]

Auch wenn sich der Sinn einer Investition in Celera immer wieder in Frage stellt, hier meine Gründe dafür:
a) Celera hat mit Craig Venter einen äußerst agilen Promoter, der mit Sicherheit noch viele (kurssteigernde)Ideen produziert.
b) ist Craig Venter klug genug zu wissen, daß seine Firma eine Perspektive benötigt um Geld zu verdienen.
c) die Kriegskasse gut gefüllt ist, um für Jahre seine Mannschaft zu bezahlen.
d) diese Mannschaft wohl aus den besten Biotechspezialisten zusammengesetzt ist.
e) der Beweis erbracht wurde, daß diese Firma in der Lage ist, etwas binnen weniger Monate zu realisieren, wofür andere Jahre verbraten.

Wir sollten uns darüber im Klaren sein, daß das GENOM-Projekt ohne den intensiven Antrieb durch Celera noch längere Zeit in Anspruch genommen hätte, wohltuend für die Budgets der beteiligten Länder.

[Shopping]

Monday June 26, 2:44 pm Eastern Time
*TOP NEWS* Human Genome
Top News Summaries on Other Subjects


World general [TOP/G] Sports [TOP/SPO]

Business [TOP/BIZ] Emerging Markets [TOP/EMRG] .....

For news and data, double-click on the codes in brackets. Access to some items may depend on subscription level. .....

Top Stories

> First step of human gene map finished [nL25350233] > Public, private teams cooperate on genome-Clinton [nWAT021663] > Celera says Immunex signs up for its genomic datab[nN26704602] > Genome allows scientists to pinpoint cancer causes[nL21349587]


> New companies scramble to exploit human genome [nN26386905]
REACTION
> France stresses genetic code must remain public [nL26461692]
> Sceptics fear "book of life" could spell death [nL26476394]
ANALYSES/FEATURES

> Gene map gives clues but no short cut to new drugs[nL26424098]

[starbull]

Celera hat das Mausgenom mitentschlüsselt - was ja wichtiger ist. She. WO-Beitrag von heute. Hier wird Geld verdient! Lest alle diesen Bericht nach!!

[goodi]

prima tipp dj. klasse recherchiert dein beitrag

"montag ist celera tag". weiter so und noch mehr

solcher volltreffer.

mfg.goodi

[dj-cool]

Klasse Beitrag goodi!!
Hat viel mit Recherche zu tun wenn der Kurs nicht raufgeht!!

Aber lesen scheint nicht Deine Stärke zu sein, Englisch-Kurse kann man übrigens Zuhauf bei Volksschulen belegen!!

DJ Cool

[emmi 2]

Wer hat Infos vom Nasdaq?

[goodi]

warum,ich habe vertex ?

aber mir geht es ähnlich mit commerce one.
superaktie,superfantasie teilweise schon mit guten zahlen untermauert
und nichts geht. hatte übrigens celera,human genomics
und millenium im depot. habe dann doch zugunsten
von B2B umgeschichtet,weil ich deren dynamik
höher einschätze. biotech wird noch einige empfindliche
durststrecken durchmachen,weil m.e. die umsatzdynamik
nicht(noch) mit der kursentwicklung mithalten kann.
ich denke,die zeit für biotech ist erst in 1 bis
3 jahren reif.

mfg.goodi

[Shopping]

Monday June 26, 5:11 pm Eastern Time
Celera maps human genome, but its profits seen years away
By Ransdell Pierson

NEW YORK, June 26 (Reuters) - Now that Celera Genomics (NYSE:CRA - news) has stirred wonder by sequencing the human book of life, can the Maryland company decipher how to make a buck?

Based upon its share price, many investors are optimistic the genomics company will also solve that eternal riddle -- despite the fact some analysts don`t expect Celera to turn a profit for five years or longer.

The stock of the two-year-old Rockville, Md. company hit an all-time high of $252 a share on February 25, but has retreated to the $110 range amid a sharp downturn since then in the biotech sector. Although well off its earlier highs, Celera shares are still up 1400 percent from this time last year.

When Celera (NYSE:CRA - news) was created in May 1998, the goal of the fledgling firm was to become the world`s leading supplier of information about genomics -- the study of the structure and function of genes.

The company had revenues of $12.4 million for the fiscal year 1999 that ended last June. But it reported a loss of $43.5 million amid start-up costs of hiring staff and acquiring sophisticated machines that analyse the stretches of four chemicals that make up genetic blueprints, or genomes.

It aims to become profitable by charging drug companies, universities and other researchers for subscriptions to giant databases that will detail the genetic makeup of humans as well as of other organisms whose genes are surprisingly similar to man because of our common ancestry.

For now at least, Celera is interested only in selling information -- not in making drugs, said SG Cowen analyst Eric Schmidt.

Aims to be Portal of Genomics Information


``Celera wants to be the genomics clearinghouse, the portal you will have to go to when you want information on genomics,`` Schmidt said, noting about a half dozen large drugmakers have signed subscriptions to its genomic databases in the past 18 months.

California biotech giant Amgen (NasdaqNM:AMGN - news), Swiss life sciences firm Novartis AG and New Jersey drugmaker Pharmacia Corp all signed 3-year subscription deals in 1999 worth $25 million apiece.

New York pharmaceuticals giant Pfizer Inc. (NYSE:PFE - news) and Japan`s largest drugmaker, Takeda , have both signed 5-year, $50 million subscription deals. Seattle-based biotech company Immunex Corp. (NasdaqNM:IMNX - news) has also signed up, Celera announced on Monday.

Schmidt predicted almost all important drugmakers will eventually sign on as Celera subscribers and that many universities will likely subscribe, paying a smaller fee than drug companies to the same Internet-accessible databases.

``Anyone in the business of genetic research could be a Celera customer, including pharmaceuticals companies, universities, hospital labs and even physicians on Main Street,`` said Schmidt. Nevertheless, he predicted the company won`t become profitable for at least several more years.

Revenues Soar, but Profits Seen Years Away


William Blair & Co. analyst Winton Gibbons forecast that Celera will report revenues of $41 million for the fiscal year 2000 ending June 30, but a loss of $1.73 per diluted share.

Revenues will likely more than double to $84 million in 2001 and jump to $145 million in fiscal year 2002 as more subscribers come aboard, he added, with respective losses growing as well to $1.95 and $2.04 per share.

Ed Bloch, a Celera spokesman, said on Monday the company had not yet predicted when it will become profitable.

Gibbons, however, thinks that milestone won`t be reached for five years or so.

``By the year 2004, we expect Celera to break even with revenues of $400 million to $800 million. After that, profits could expand enormously because it will have already paid to build its databases`` and will therefore make high margins on all new subscriptions, Gibbons said.

Gibbons said Celera will probably wind up making two-thirds of its revenue from its databases and the rest from contracts to do special research for customers, such as helping a drugmaker track down genes that cause Alzheimer`s Disease.

Databases to Include Humans, Mice, Other Organisms


Celera has said its Human Genome Database will provide the complete sequence of the human genome, including the entire collection of scores of thousands of human genes and notations of how they are linked to diseases and biological processes.

A separate ``SNP`` database will detail the slight variations in the genetic code of different individuals, based initially on Celera`s ongoing sequencing of genomes of six men and women of different ethnic backgrounds.

DNA consists of only four chemicals, which pair off in over 3 billion individual steps on a spiral-shaped molecule. Although 99.9 percent of the steps are identical in human beings, an estimated 30 million steps vary among individuals and explain their different predisposition to diseases.

Such switches in the chemical pairs are called SNPs, or single nucleotide polymorphisms, and Celera has said it is well along in identifying them and placing them in their own database.

Other Celera databases will detail the genetic sequences of various organisms. By being able to compare genes of the different creatures, a task called comparative genomics, Celera believes researchers will be much better able to pinpoint genes linked to human diseases. Drugs could then be designed to turn off harmful genes, or to turn on helpful ones.

Celera last year announced it had already sequenced all 120,000 pairs of chemicals that form the genome of the fruit fly, whose tiny size belies its enormous importance as an experimental organism in research labs over the past century.

The mouse, that other most-studied organism for hints about causes of human ailments, has a genome with roughly the same number of chemical pairs as humans. Celera has already sequenced over 1 billion of them -- about a third of the job -- with powerful gene-sequencing machines supplied by its sister company, PE Biosystems (NYSE:PEB - news) of Foster City, Calif.

``Changes in their (mice) genetic material can teach us how changes in the letters of human DNA lead to predisposition to disease and responses to medical treatment,`` Celera`s chief scientific officer Craig Venter said earlier this month.

The rat, the chimpanzee, the horse and the pig are believed leading candidates to be sequenced next by Celera, although the company has not confirmed any such lineup.

Proteomics Seen as Next Big Push


SG Cowen`s Schmidt said Celera will also move strongly into the area of proteomics, a growing field in which researchers describe the characteristics, function and complicated inter-relationships between proteins that are encoded by the estimated 50,000 or more genes in human DNA.

``The genome is a blueprint of life, but to understand how to build a house around that blueprint you need to better understand proteins`` which drive all chemical reactions in the body, said Schmidt.

Schmidt said he expects Celera to spend hundreds of millions of dollars in the next few years to buy equipment, including mass spectrometry machines, that can identify proteins and help explain how they interact. Information gleaned from that research will be put into special protein databases, he said.

The analyst said Celera`s biggest rival is Incyte Pharmaceuticals Inc (NasdaqNM:INCY - news), a Palo Alto, Calif.-based company that claims to have the world`s most extensive commercial database on the human genome.

``Both Celera and Incyte certainly could become stand-alone viable businesses in the long term,`` said Schmidt, who added he was placing the most faith in Celera.

Shares of Celera fell 12-7/16 to 112-9/16 Monday on the New York Stock Exchange. Analysts said investors took profits on news the company and a publicly supported consortium, the Human Genome Project, that sequenced the human genetic blueprint by a different method, would cooperate in publishing their findings. The Human Genome Project includes researchers from the U.S. and Europe.



Email this story - View most popular stories emailed


--------------------------------------------------------------------------------
More Quotes
and News: Amgen Inc (NasdaqNM:AMGN - news)
Immunex Corp (NasdaqNM:IMNX - news)
Incyte Genomics Inc (NasdaqNM:INCY - news)
PE Corp (Celera Genomics Group) (NYSE:CRA - news)
PE Corp (PE Biosystems Group) (NYSE:PEB - news)
Pfizer Inc (NYSE:PFE - news)

[stockstudi]

Das ist die Börse! Einen Großteil meiner celera -Aktien hat es schon per stop/loss am Nachmittag aus dem Depot geschossen. Ein Teil bleibt weiterhin langfristig investiert. Aber über eines sollten sich nun alle Investoren einig sein: Die Chance wirklich profitable Patente z. B. auf das Gen gegen Haarausfall zubekommen tendiert gegen Null. Hier lag das enorme Potenzial. Celera verkauft diese Gene an Pharmaunternehmen gegen eine einmalige Gebühr und kassiert weiterhin im Erfolgsfalle prozentual am Verkaufserlös der Substanz mit-*Schnee von gestern. Ich bin gespannt ,wie Venter das Unternehmen in die Profitzone bringen will oder wird. Für mich ist celera jetzt nur noch ein untergeordneter Wert,der rel. klein im Depot bleibt.

Wünsche allen loosern von heute,einschließlich mir,eine angenehme Nacht. Börse ist wie alles im Leben: Mal gewinnst Du ,mal verlierst Du. Es kommt nur darauf an ,daß Du von 100x mind.51 x richtig liegst.

Gruß stockstudi

[dj-cool]

Man kann sich jetzt jeder Meinung im Board anschließen, denn überall ist etwas logisches dabei!!
Ich für mich bleibe in Celera investiert, weil ich mich jetzt fast schon 8 Monate intensiv damit beschäftige!
Deswegen kann ich auch andere Meinungen im Board nur bestätigen das es bei Celera meist "Sell on good news" gab, vor allem nach dem Statement von Clinton und Blair, weil Investoren bei jeder Meldung noch etwas aus dem Hinterhalt erwarten.
Aber ich habe diesen Wert so oft 100 % gewinnen sehen und dann wieder 50 % verlieren und deswegen bleibe ich optimistisch, denn alles was fällt steigt auch wieder, ob nun morgen oder erst in 2 Wochen!!
Außerdem passt das ganze was gestern passiert ist alles überhaupt nicht zu Venter!!
Jeder muß allerdings selber entscheiden was er tut, ich bleibe drinnen
aber mein Kursziel von gestern war ja ein absoluter Fehlgriff!!
Vielleicht täusche ich mich diesmal auch wieder!!
Ich bin aber immer noch von Celera total überzeugt und habe mich vielleicht ein bißchen von derart weitgreifenden News blenden lassen, aber Celera kommt egal ob in 1 Woche oder in 1 Jahr!

Grüße DJ-Cool

[dj-cool]

Menschliches Genom komplett sequenziert

In einer bewegenden und live gesendeten Übertragung wurde heute die vollständige Sequenzierung des menschlichen Genoms bekanntgegeben. Dabei wurden die Ergebnisse simultan in London (Nr. 10 Downing Street) in und Washington (Weißes Haus) der Öffentlichkeit vorgestellt.
An der Zeremonie wirkten Präsident Bill Clinton und der britische Premierminister Tony Blair mit, die mit ihrer gemeinsamen Rede im März den Kursrutsch bei den Biotechnologiewerten ausgelöst hatten.
Hauptredner waren der Präsident und CEO von Celera und der Vertreter des öffentlich finanzierten Human Genom Projekt, Dr. Francis Collins.
Mit der heutigen Veröffentlichung der Gendaten ist die Arbeit jedoch keineswegs abgeschlossen. Zumal es sich nur um eine „erste Rohfassung“ des menschlichen Genoms handelt. So richteten die Redner ihr Augenmerk in die Zukunft, in der man mit vereinten Anstrengungen weiterarbeiten will.
Auch die Angst vieler Menschen vor den neuen Möglichkeiten ,die die Gentechnik uns eines Tages bieten wird, nahm weiten Platz in den Reden ein. Man habe Sorge zu tragen, dass gewonnene Daten ausschließlich zum Nutzen eingesetzt werden dürfen, und niemals zur Diskriminierung einzelner – so die einhellige Meinung.

Alle waren sich jedoch einig, dass dieser heutige Tag einen großartigen Wendepunkt für die ganze Menschheit darstelle – oder wie Bill Clinton es knapp formulierte:

„This is a great day! “.

Ungeachtet dieses gewaltigen Schrittes der Menschheit hin zum Verständnis ihrer selbst, gehören die Aktien des Pioniers in diesem Segment - Celera - heute eindeutig zu den Verlierern. Nachdem sich die heutige Veröffentlichung schon seit einigen Tagen anzeichnete, hatten sich zahlreiche Investoren schon vorher reichlich eingedeckt, und heute die Gelegenheit zu Gewinnmitnahmen genutzt.

[dj-cool]

Human Genome: We Have the Map, So Where`s the Treasure?
By Dane Hamilton
Staff Reporter
6/26/00 8:15 PM ET



The human genome has now been mapped, mostly. Now what?

With all the hype surrounding this achievement announced Monday by Celera Genomics (CRA:NYSE - news) and the Human Genome Project, one might be forgiven for thinking we`re on the verge of finding cures to the great diseases that have plagued mankind for millennia. And the answer is, er, not quite yet.

The utility of the map of the human genome in finding new drugs is still a long way off -- as are the revenue and profits that could come with it, experts say. And some investors say that this disappointment could be behind the selloff Monday in genome stocks such as Celera, Incyte (INCY:Nasdaq - news) and Millennium (MLNM:Nasdaq - news).

"I think the market in general was expecting some jewel of a statement quantifying what it all means," says David Saks, who manages the Gruntal Medsciences Fund, a New York biotech fund with assets of around $150 million. "But the jury is still out as to who and which companies are going to be the beneficiaries."

Analysts and investors generally agreed that Monday`s announcement was indeed momentous from a scientific and technological viewpoint. Using advanced computer technology, Celera, a PE Biosystems (PEB:NYSE - news) unit, and a public consortium managed by the government`s National Human Genome Research Institute, produced a working map of what it said was the correct order of the chemical units that make up deoxyribonucleic acid (DNA), the molecule that generates the proteins that make up the human body.

Digging for Gold
But having the map of where treasure may be and finding the gold in the form of new drugs is a giant leap that`s just beginning. And drug companies haven`t waited for the map to come out before scrambling to find the gold nuggets -- the estimated 40,000 or so genes -- that are nestled in the 3.12 billion "base pairs" of DNA strands that comprise the human genome. The genomic map disclosed Monday is 97% useless from a therapeutic and medical point of view, scoff some observers.

"From the point of view of the biotech and pharmaceutical industry, this is a nonevent," says William Haseltine, chairman and chief executive of Human Genome Sciences (HGSI:Nasdaq - news), a Maryland biotech company that has been developing new drugs based on genetic research for several years. Haseltine says the event is more of a marker of human achievement than an advancement that will immediately lead to new drugs.

In recent years, drug makers have made major strides in fighting some diseases that have a genetic component, with an early biotech victory being the synthesis of the insulin protein for diabetics. But being able to alter those defective genes that can fuel the development of cancer and heart disease is still in the nascent stages.

"We`ve known the cystic fibrosis gene for 11 years, but knowing the gene and getting a drug is no easy step," says Mark Augustine, an analyst with U.S. Bancorp Piper Jaffray. Having a genome map, he says, "is a jumping-off point." Furthermore, "you may have 25 or 30 genes that have something to do with any given disease."

Hey, Great Job!
The utility of the map of the genome didn`t figure highly into Monday`s news conference, however. Instead, there was much backslapping about finding the proper order of the four chemicals that form the basis for DNA: adenine, cytosine, guanine and thymine, complete with awe-inspiring imagery. For instance, if the genome map were printed on 8.5-by-11-inch paper and piled up, the paper tower would be the height of the Washington Monument, according to Craig Venter, Celera`s president and chief scientific officer.

Celera`s Venter and Francis Collins, head of the National Human Genome Research Institute, acknowledged that the latest draft of the human genome isn`t 100% complete, but that it contains "gaps" that still are being filled.

And, the process of annotating and interpreting the information in the genome map is likely to take years. Of particular importance will be identifying the active genes, segments of chromosomes that play a role in the creation of proteins, and so-called single nucleotide proteins, variations in human DNA that may indicate susceptibility to disease for individuals.

"We`re still years away from any meaningful drug," says Jeff Paley, an internist at New York Hospital who follows the biotech industry. "From a medical point of view, it means absolutely nothing. And anyone who buys stocks for this reason is slightly misinformed."

[dj-cool]

Hier ein Artikel den ich für sehr sehr interessant halte und der ganz gut die Lage von gestern beschreibt!!
Ich verzichte auf Interpretationen und Kommentare, da ich die letzten Tage nicht sonderlich Glück hatte damit, aber wie schon gesagt sehr sehr interessant!!

Grüße DJ-Cool



Celera Turns the Other Cheek


By Jeff Fischer (TMF Jeff)
June 26, 2000

Mama mia!

Bill Clinton and Tony Blair ushered in the announcement that the first map of the human genome has been completed. Afterward, they stepped aside and let Francis Collins, the head of the Human Genome Project (HGP), and then Craig Venter, the mind that leads Celera (NYSE: CRA) -- and the mind that arguably made today happen today, and not several years from now -- have their words.

Reading the transcripts from the press conference and seeing some of the ceremony on video, it was probably apparent to anyone with knowledge of the situation (which is relatively few people, unfortunately) that "a whole lotta politics was goin` on."

And because of those politics, Celera essentially received second billing for its accomplishment. The company has mapped the genome of five individuals with paired sequence reads that cover the genome 35.6 times. The Human Genome Project is only 85% finished with its map of the genome. Still, Celera shared the stage with the government`s Human Genome Project and Celera is sharing headlines with Clinton, Blair, and Collins -- which is OK, except that Celera is typically mentioned last in the whole lineup.

I don`t mean to be a nitpicking guy. Really! But if ever there were one media event meant to please most everyone involved and save face, and then one separate set of facts that will be written in the history books (and subsequently will make that media event trivial), this was one such event. Celera shared its accomplishment generously and in doing so it was given second billing.

That`s politics for ya. The government funded the Human Genome Project for a long time. If a private company emerged and made it look bad (as, um, Celera did) the government would look bad, too. Also at stake: Clinton wants the genome map to be part of his legacy. The only way he can accomplish that is to give credit to the Human Genome Project. And I`m not begrudging that. The Human Genome Project deserves a great deal of credit. Just not top billing when it was Celera that made today possible. If not for Celera, the Human Genome Project may not have finished its work until at least 2002 (which would have been far too late for Clinton, incidentally).

Anyway, enough politics. What today means was best described, I think, by Collins: "We`ve been racing down white water in a narrow channel trying to get the sequencing done. Now we`re opening into the [slow, expansive] ocean."

In that ocean are endless possibilities for medicine that demand to be discovered. Everyone has said many times, including us, that this discovery will take a great deal of time. Venter reminded us today, though, that many discoveries probably won`t take as long as most people expect. Technology is moving so quickly that in many cases, what took science 10 years to accomplish one decade ago can now be completed in months.

This is excellent news for science and for our health. As investors, however, it`s prudent for us to continue to err to the conservative regarding our expectations. So, we`ll continue to assume that major drug discoveries due to the genome map won`t begin to appear for a long, long time, and we`ll continue to remind ourselves that drug trials and FDA approval take many years longer.

Venter stated today that the next step is the "interpretation" phase, meaning now the true work begins: find out what everything in the genome means, and even "what makes us alive." Alongside that, there is important business to take care of at Celera if it is to survive long-term alone. (How strong a factor money is in all of our lives!) Celera`s second main focus now is to sign new customers. Today Immunex (Nasdaq: IMNX) signed with Celera under a new royalty-sharing contract. When Immunex completes revenue-generating discoveries using Celera`s data, Celera receives royalties on sales.

In the past, companies like Pfizer (NYSE: PFE) paid $50 million for straight access to Celera`s data for five years. At least three other companies, including Amgen (Nasdaq: AMGN) , paid $25 million for three-year contracts. Royalty relationships are new to Celera and could prove to be the largest revenue stream someday, assuming bioinformatics proves as valuable as Celera believes. Royalty sharing is a logical contract to sign in bioinformatics business deals, but we might also speculate that royalty relationships were necessary to stir up more business at Celera. A subscriber`s risk is much lower if the company only pays Celera very meaningful cash upon a successful discovery. On the negative side for Celera, up-front payments are immediate cash flow. Waiting years for a discovery is not.

Either way, what`s most important to investors now is new subscribers. We want to see Celera announce several subscribers in the near-term. So, here we are: living, breathing collections of genes -- about which Celera knows more than anyone --watching our company while at the same time it unravels us.

(Certainly melodrama is underrated!)

[dj-cool]

Und noch ein interessantes Statement vom gleichen Autor zu "sell on good news"

DJ-Cool


Buy on the Rumors, Sell on the News?!
Celera and The Human Genome Project mark historic day

By Ann Coleman (TMF AnnC)
June 26, 2000

Did you catch CNN this morning? I almost never turn the TV on during the day. I`m afraid I will be ambushed by Jerry Springer or, worse, Barney. But, today I happened to catch the live press conference from the White House announcing the completion (mostly) of the human DNA map.

President Clinton and British Prime Minister Tony Blair, probably both very mindful of their misinterpreted statements back in March that caused the whole biotech sector to tank, spoke in glowing terms about the achievement of PE Celera (NYSE: CRA) and the non-profit Human Genome Project, and about this achievement`s potential to improve the quality of life for everyone on the planet.

It was thrilling. I swallowed it all, lock, stock, and barrel. I don`t care if the spin machine was on, I don`t honestly think one can overstate the importance of this scientific milestone. It`s like July 20, 1969... maybe even better, although the relative importance of our first venture into space versus the mapping of the human genome is something future historians will have to decide.

It will be awhile before the knowledge base is put to the kind of use that will affect most of us directly. That`s always the way with scientific breakthroughs. First a few benefit, then the many. I am holding out for a genetic breakthrough that will make me tan without all that tedious sunbathing, and something to return my hair to its youthful golden sheen would be appreciated, too.

Does that strike you as trivial? It was meant to. Curing cancer and genetic diseases is the noble and rightful goal of this research, but what will ultimately pay the bills will probably be a host of very trivial but highly desirable products designed for mass audiences.

I was thinking about the whole credit card thing today. (Yes, this is still the same column.) A reader wrote in describing how his family had broken out of the debt trap and that got me thinking about consumerism. It`s a paradox, really. Our economy is run by consumer goods. All of the BMW-driving, Eddie Bauer-wearing soccer parents and each of their 2.1 Sega-playing children contribute to the development of an economy that supports this kind of grand scientific research.

People who avidly consume keep the capitalistic wheels greased and make civilization as we know it possible. Yes, literally. Yet, those who buy too avidly can pay a high and very uncomfortable price for their part in fueling economic growth, while those who opt out of much of the consumer mentality can still reap the rewards of that growth. Of course, if everyone opted out as much as I do, we wouldn`t have an economy that could support the arts, science, medicine, or philanthropy. Thank you, yuppies, and the yuppie puppies, too.

The genetic research going on right now has so much potential that it`s difficult to list the most likely applications, and I am certain if I did list them, I would find that list laughable in 20 years. One thing I will predict is that consumer products will come from this discovery -- and we will want them. And they will fuel economic growth and grease the wheels of the next great discovery. I can`t wait to see what happens next.

Meanwhile, Celera, which played a major role in the fast completion of the project, fell 10% after its president, J. Craig Venter, got his handshake from President Clinton. Does that strike you as weird?

One of the less-useful Wall Street proverbs is: Buy on the rumor, sell on the news. That`s what happened with Celera. It has been going up dramatically in the last few weeks as investors anticipated this announcement (which was not much of a surprise). When the announcement was made, apparently quite a few stockholders decided to sell on the news.

That kind of short-term trading mentality isn`t very Foolish. I own shares in both Celera and Human Genome Sciences (Nasdaq: HGSI) , another biotech company that will profit from the genome map, and I consider them quintessential buy-and-hold stocks. Which doesn`t mean I think you should buy them. For me, they are an exciting, but risky, way to connect to the future. But, one of the things I like best about them is that they have the potential to create millions of healthy, affluent customers for General Motors, Kodak, Caterpillar, and J.P. Morgan.

Speaking of which... the Foolish Four finally went up today. All our stocks except GM were in the green for a change, but the portfolio still looks pretty pitiful. The slide over the last several weeks has not been one bit of fun.

Check back here on Thursday and Friday for a discussion of the research project that we will be undertaking as soon as our new database arrives. The first order of business will be to explore the validity of the RP ratio as a predictor of future stock performance outside the Dow. Then we will look at possible improvements to the strategy.

By the way, I am not expecting any strategy that selects out-of-favor, large-cap stocks will have done particularly well recently. That would be nice, but we can`t skew the research to pick something that does well in one particular type of market. Right now the market is all about the new economy, and it will probably stay that way until people catch on to the fact that the new economy is creating lots of customers for old-economy stocks, too.

Finally, tonight at 7 p.m. ET, David Gardner and Jeff Fischer will discuss the biotech industry in a Yahoo! chat.

Fool on and prosper!

[dj-cool]

Was sagt Euch das ?

Institutional Holdings Summary For PE CORP.-CELERA GENOMICS: CRA (Amex)
Latest Quarter Previous Quarter 2 Quarters Ago 3 Quarters Ago
% Inst Owned: 70.1% 66.7% 70.2% 47.5%
Shrs Bought: 12,403,490 6,497,082 17,624,696
Shrs Sold: 10,589,163 8,344,551 5,778,434
Net Bought(Sold) 1,814,327 (1,847,469) 11,846,262
# Inst Owning: 213 168 104 77
# Buyers: 125 98 58
# Seller: 97 46 40
Net Buyers(Sellers): 28 52 18

[dj-cool]

Man sollte Venter und Celera nicht unterschätzen! Bedenkt doch einmal, daß Celera alle Projekte die Sie angegangen sind innerhalb des gesetzen Zeitraums und mit dem dazu vorhandenen Kapital umgesetzt haben! Wie lange forscht das HGP schon an dem kompletten menschlichen Genom?? Die Antwort wisst Ihr selber! Wie lange hat Celera gebraucht?

Was würdet Ihr dafür zahlen wenn Ihr Euer Leben vordoppeln könntet oder eine Krankheit hättet die bislang noch nicht zu bekämpfen wäre!!

Utopie?

Patent oder nicht? Wer war bislang der schnellste in dem Rennen um Genentschlüsselung ob bei Menschen, der Fruchtfliege oder der Maus?
Richtig! Celera!

Es wird andauernd über den Zeitraum geredet wann Medikamente durch die Genentschlüsselung auf den Markt kommen! 10 Jahre oder mehr! Aber:
Stellt Celera sie Medikamente her? Nein

Große Firmen wie Schering etc. werden das übernehmen!

Aber um überhaupt ein Medikament herzustellen das das Leben verdoppeln würde müßte erst das Gen ausgegrenzt und erforscht werden das die sogenannte Biologische Uhr steuert!

Und wer wird das tun? Celera, oder glaubt Ihr ernsthaft das das HGP in solchen Sachen schneller sein wird als Celera? Wer hat die weltbesten Forscher und das neueste Equipment?

So und zum Schluß noch eine Frage: Wieviel werden die großen Pharmaunternehmen und sonstige Firmen wohl für derartige Informationen zahlen? Ich weiß es nicht, denke aber das Sie bereit wären eine Menge dafür locker zu machen!

Und da wäre nicht nur das eine Gen oder die eine Gensequenz! Aids, Krebs, Knochenschwund, vererbliche Krankheiten ...............

Und Celera wird der global player in Sachen Erforschung der Funktionen der Gene sein und werden!

Es werden mich jetzt sicherlich einige für verrückt erklären aber so sehe ich Celera als Long-Term Strong Buy!

[dj-cool]

Immunex kauft sich in CRA Datenbank ein!


Company Press Release
SOURCE: Immunex Corporation
Celera Genomics to Provide Database Subscription to Immunex Corporation
ROCKVILLE, Md., and SEATTLE, June 27 /PRNewswire/ -- Celera Genomics (NYSE: CRA - news), a PE Corporation business, and Immunex Corporation (Nasdaq: IMNX - news) today announced that they have entered into a five-year comprehensive genomics agreement including a subscription to all of Celera`s current database products.

The database subscription by Immunex gives its researchers access to four databases developed by Celera until 2005. All four of Celera`s databases include Celera proprietary information as well as publicly available data. First, the Celera Human Gene Index provides customers with the set of human genes derived from EST sequencing programs. Second, Celera`s Human Genome Database is expected to provide the complete sequence of the human genome and the entire collection of human genes with links to associated biological and disease information. Third, the Drosophila Genome Database provides the complete sequence of the Drosophila melanogaster genome sequence generated by Celera`s whole genome shotgun sequencing strategy. The Drosophila genome database is extensively annotated with gene, protein and biological information. Fourth, the Mouse Genome Database being generated by Celera should allow for comparative analysis with the human genome that may be especially significant for the identification of genes and gene regulatory regions of importance to understanding human biology. Access to the databases also provides Immunex with associated comprehensive bioinformatics systems and tools for viewing, browsing, and analyzing genomic information.

``The subscription agreement between Immunex and Celera demonstrates the next step in realizing the significance of gene discovery,`` said Craig Venter, Ph.D., Celera`s president and chief scientific officer. ``It is important because it brings together the research and development resources at Immunex with Celera`s unique ability to provide researchers with accurate human genome sequence, tools to identify and understand genes and regulatory functions, qualitative comparisons with other genomic sequences, and powerful bioinformatics capabilities.``

``Celera`s genomic databases represent an important milestone in the sequencing of the human genome,`` said Doug Williams, executive vice president and chief technology officer of Immunex. ``This information should provide Immunex researchers with a valuable tool for identifying important genes involved in disease areas in which Immunex has proven expertise. The quality of the sequencing data and the bioinformatics capabilities that Celera should provide will significantly accelerate our own research and discovery processes.``

PE Corporation comprises two operating groups. The Celera Genomics Group, headquartered in Rockville, MD, intends to become the definitive source of genomic and related medical information. The PE Biosystems Group (NYSE: PEB - news), headquartered in Foster City, CA and with sales of $1.2 billion during fiscal 1999, develops and markets instrument-based systems, reagents, software, and contract related services to the life science industry and research community. Information about the company, including reports and other information filed by the company with the Securities and Exchange Commission (SEC), is available on the World Wide Web at http://www.pecorporation.com or by phoning 800-762-6923.

Immunex Corporation is a biopharmaceutical company dedicated to improving lives through immune system science innovations.

American Home Products owns a majority interest in Immunex. AHP is one of the world`s largest research-based pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of prescription drugs, including biotechnological and vaccine products, animal health care products and over-the-counter medications.

This release contains forward-looking statements that involve risks and uncertainties, including risks associated with clinical development, regulatory approvals, patent litigation, product commercialization and other risks described from time to time in the SEC reports filed by Immunex, including the most recently filed 10-K and 10-Q forms. For more information, please refer to www.immunex.com.

Certain statements in this press release are forward-looking. These may be identified by the use of forward-looking words or phrases such as ``believe,`` ``expect,`` ``anticipate,`` ``should,`` ``intend,`` ``planned,`` ``estimated,`` and ``potential,`` among others. These forward-looking statements are based on PE Corporation`s current expectations. The Private Securities Litigation Reform Act of 1995 provides a ``safe harbor`` for such forward-looking statements. In order to comply with the terms of the safe harbor, PE Corporation notes that a variety of factors could cause actual results and experience to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. The risks and uncertainties that may affect the operations, performance, development, and results of Celera Genomics` businesses include but are not limited to (1) operating losses to date; (2) a unique and developing business plan; (3) dependence on the timely completion of the sequencing and assembly of the human genome; (4) uncertainty of revenue growth; (5) unproven use of genomics information to develop products; (6) intense competition in the evolving genomics industry; (7) dependence on customers in and subject to the risks of the pharmaceutical and biotechnology industries; (8) heavy reliance on strategic relationship with the PE Biosystems group; (9) potential product liability claims; (10) liabilities related to use of hazardous materials; (11) lengthy sales cycle; (12) dependence on the unique expertise of its scientific and management staff; (13) uncertainty of patent, copyright and intellectual property protection; (14) dependence on computer hardware, software, and internet applications; (15) access to biological materials; (16) legal, ethical and social issues affecting demand for products; (17) disruptions caused by rapid growth of the business; (18) government regulation of its products and services; (19) risks of future acquisitions; and (20) other factors that might be described from time to time in PE Corporation`s filings with the SEC.

NOTE: Celera, Celera Genomics, and PE Biosystems are trademarks of PE Corporation.

SOURCE: Immunex Corporation

[dj-cool]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[dj-cool]

Investors cash in, Celera stock falls
Analysts say volatility in genomics shares is likely to continue
--------------------------------------------------------------------------------
By Julie Bell
Sun Staff
Shares of Celera Genomics Group took a beating yesterday as investors cashed in the same day the company made the triumphant but long-anticipated announcement that it had assembled the human genome.

The Rockville company`s stock traded as low as $108 before closing at $114, down $13, or 10.2 percent. Other genomics stocks also were hit hard early in the day. The Nasdaq Biotechnology Index fell 14.5 percent before enthusiasm about prospects for genomics and biopharmaceuticals brought it roaring back to close at 1,216.34, up nearly 4 percent.

"This is a major milestone, no doubt," Stefan D. Loren, an analyst with Baltimore-based Legg Mason Wood Walker, said of the assembly of the genome, which contains the genetic directions for building and running the human body. "What people really want to see is drugs come out of this."

In the short-term, analysts said yesterday, trading in shares of genomics companies such as Celera and Human Genome Sciences Inc., also of Rockville, should continue to be volatile as investors pile into them in anticipation of announcements, then bail out with profits upon news like yesterday`s.

Analysts said the long-term outlook for the sector is extremely good, though investors will get more sophisticated about differentiating among companies based on their performance.

"The whole group will be a leadership group in stocks going forward," said biotechnology sector analyst Paul R. Knight of Thomas Weisel Partners in New York. "It`s just beginning."

The sector encompasses companies that are researching and developing gene-based drugs, and companies such as genomics-information provider Celera that provide tools to do that.

Celera has added the human genome to its giant databases of information about genes and proteins. Pharmaceutical and university-based researchers buy subscriptions to the databases, which they use to look for naturally occurring substances in the body to treat disease.

Yesterday, Celera said that an eighth subscriber to that information - Seattle-based biopharmaceutical company Immunex Corp. -- had signed up. It also said it had compiled a database of about 6 million variations in the genetic code among individuals, information important to pharmaceutical companies looking for clues to why a drug that works for one person could be toxic for another.

Companies in the sector are pursuing different strategies. Santa Clara, Calif.-based Affymetrix sells tiny biochips that help analyze which genes are active and how they`re functioning, while Human Genome Sciences is working to turn its research on gene makeup and function into biopharmaceuticals. Last week, Human Genome announced that it would begin using human subjects to test a naturally occurring protein designed to treat immune-system disorders in patients with AIDS and other diseases.

In a prime example of how widely genomics stocks can swing on the news of the day, Human Genome shares rose 9.3 percent Friday on the news that day, then fell as much as 13.3 percent yesterday as investors cashed out after Celera`s joint announcement with a public project that it had finished a 90 percent rough draft of the genome.

By day`s end, Human Genome Sciences had rebounded to close down $2, or 1.4 percent, at $143.375.

Celera has swung widely over the past several months, peaking at $247 on March 6 before dipping to a six-month low of $51.375 late last month. The movement of biotechnology stocks in general has mirrored Celera`s.

Still, said analyst Eric Schmidt of SG Cowen Securities Corp., "In the long term, we`re huge fans of companies like Celera." He said Celera`s announcement of an eighth subscription customer yesterday "provided more validation, if you needed more, that Celera has the goods."



Originally published on Jun 27 2000


--------------------------------------------------------------------------------

[matthze]

Celera-Kurs 105 1/4 um 15.49h. Ich glaube jetzt gehts nach unten, rette sich wer kann!

[matthze]

Celera-Kurs 106 5/16 um 15.50h. Ich glaube jetzt gehts nach unten, rette sich wer kann!

[Shopping]

Tuesday June 27, 10:13 am Eastern Time
Celera says Immunex signs 5-yr database subscription
NEW YORK, June 27 (Reuters) - Celera Genomics (NYSE:CRA - news) said on Tuesday that Seattle biotech company Immunex Corp. (NasdaqNM:IMNX - news) signed a five-year subscription to Celera`s four databases containing information about the genetic codes of human beings and other organisms.

``The database subscription for Immunex gives its researchers access to four databases developed by Celera until 2005,`` the companies said in a prepared release. A Celera spokesman said financial terms were not immediately available, but several companies that have previously taken five-year subscriptions have committed to paying Celera $50 million each.

Craig Venter, president and chief scientific officer of Celera, had announced on Monday that Immunex agreed to subscribe to its four proprietary databases. The databases are expected to include complete sequences of the human genome and the entire collection of human genes with links to various diseases, as well as complete genetic sequences of the mouse and fruit fly.

``Access to the databases also provides Immunex with associated comprehensive bioinformatics systems and tools for viewing, browsing, and analysing genomic information,`` the statement said.

Immunex, whose shares are majority owned by U.S. drugmaker American Home Products Corp (NYSE:AHP - news), sells the blockbuster arthritis drug Enbrel. Celera, based in Rockville, Md., captured the the world spotlight on Monday when it announced it had sequenced about 99 percent of the 3.1 billion chemical pairs that make up the human book of life.

[dj-cool]

22.05.2000
Celera 3-Jahres-Kursziel 271 USD
Morgan Stanley Dean Witter


Die Wertpapierspezialisten Douglas D. Lind und seine Kollegen von Morgan Stanley Dean Witter bewerten Celera Genomics (WKN 920954) mit „Outperform“, da die Genforschung zwar noch nicht rentabel sei, aber einigen Jahren sehr hohe Gewinne erzielen könne.

In drei Jahren sei mit einem Kursziel von USD 271 zu rechnen, denn Celera sei „DAS“ Unternehmen für Erbgutinformationen und deren Verarbeitung. Das liege vor allem daran, dass die wichtigsten Genom-Forscher im Namen von Celera arbeiteten, und an dem weltweit einzigartigen Equipment.

Das wichtigste Projekt - die Entschlüsselung des menschlichen Genoms - schreite viel schneller als erwartet voran, so dass eine Fertigstellung noch im Jahr 2000 in Sicht sei. Es werde erwartet, dass sich bis zum Jahr 2010 ca. 2.000 Forschungseinrichtungen mit Informationen von Celera versorgen ließen; das alleine bedeute einen Umsatz von USD 60 Mio.

Problem der Genforschung sei jedoch, dass man noch zu wenig über die Marktentwicklung der nächsten zehn Jahre wisse, die auch von der Einstellung der Investoren und Politiker gegenüber der Gentechnologie abhänge. Außerdem sei der Konkurrenzdruck z.B. vom Human Genome Project oder dem SNP Konsortium, sehr hoch.

Das Researchteam erwartet jeweils einen Verlust pro Aktie von 1,66 USD in 2000 und 1,38 USD für 2001 nach einem minus von 0,79 USD in der vergangenen Geschäftsperiode

[dj-cool]

Celera bei 98 3/4 geschlossen! Nun ja schaun wir mal was heute passiert und was Meister Alan macht!!

Grüße DJ-Cool

[dj-cool]

<p> <img src="http://www.celera.com/images/logobluew.gif" width=241 height=90 border=0> <p/>

[dj-cool]

<p><img border="0" src="http://www.celera.com/images/journey.jpg" width="931" height="584"><p/>